

(10) **Patent No.:** US 12,383,194 B2
(45) **Date of Patent:** Aug. 12, 2025

A61M 2205/35 (2013.01); *A61M 2205/502*
(2013.01); *A61M 2230/04* (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56)

References Cited

U.S. PATENT DOCUMENTS

3,702,431 A	11/1972	Pinckaers
3,710,041 A	1/1973	Hayashi et al.
3,719,830 A	3/1973	Ananiades
4,610,259 A	9/1986	Cohen et al.
4,960,128 A	10/1990	Gordon et al.
4,964,408 A	10/1990	Hink et al.

(Continued)

(73) Assignee: **Masimo Corporation**, Irvine, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 46 days.

(21) Appl. No.: 16/752,303

(22) Filed: **Jan. 24, 2020**

(65) **Prior Publication Data**

US 2020/0229729 A1 Jul. 23, 2020

Related U.S. Application Data

(62) Division of application No. 13/911,939, filed on Jun. 6, 2013, now Pat. No. 10,542,903.

(60) Provisional application No. 61/703,747, filed on Sep. 20, 2012, provisional application No. 61/656,974, filed on Jun. 7, 2012.

(51) **Int. Cl.**

A61B 5/00 (2006.01)

A61B 5/372 (2021.01)

A61B 5/389 (2021.01)

A61M 5/172 (2006.01)

(52) U.S. Cl.

CPC *A61B 5/4821* (2013.01); *A61B 5/372*
(2021.01); *A61B 5/389* (2021.01); *A61B*
5/4839 (2013.01); *A61M 5/1723* (2013.01);

FOREIGN PATENT DOCUMENTS

EP	1 741 388	1/2007
WO	WO 02/032305	4/2002
WO	WO 2013/184965	12/2013

OTHER PUBLICATIONS

US 2024/0016391 A1, 01/2024, Lapotko et al. (withdrawn)
(Continued)

Primary Examiner — Anh Tuan T Nguyen

Assistant Examiner — Jae Woo


(74) *Attorney, Agent, or Firm* — Knobbe, Martens, Olson
& Bear, LLP

(57)

ABSTRACT

The present disclosure relates to physiological monitoring to determine the depth of consciousness of a patient under sedation. The monitor includes an EEG sensor and a depth of consciousness monitor. The depth of consciousness monitor can utilize treatment data, such as patient data and/or drug profile information with an EEG signal to determine whether the patient is adequately sedated.

8 Claims, 15 Drawing Sheets



US 12,383,194 B2

Page 2

(56)

References Cited

U.S. PATENT DOCUMENTS

5,041,187	A	8/1991	Hink et al.	6,128,521	A	10/2000	Marro et al.
5,069,213	A	12/1991	Polczynski	6,129,675	A	10/2000	Jay
5,163,438	A	11/1992	Gordon et al.	6,144,868	A	11/2000	Parker
5,319,355	A	6/1994	Russek	6,151,516	A	11/2000	Kiani-Azarbayjany et al.
5,337,744	A	8/1994	Branigan	6,152,754	A	11/2000	Gerhardt et al.
5,341,805	A	8/1994	Stavridi et al.	6,157,850	A	12/2000	Diab et al.
D353,195	S	12/1994	Savage et al.	6,165,005	A	12/2000	Mills et al.
D353,196	S	12/1994	Savage et al.	6,184,521	B1	2/2001	Coffin, IV et al.
5,377,676	A	1/1995	Vari et al.	6,206,830	B1	3/2001	Diab et al.
D359,546	S	6/1995	Savage et al.	6,229,856	B1	5/2001	Diab et al.
5,431,170	A	7/1995	Mathews	6,232,609	B1	5/2001	Snyder et al.
5,436,499	A	7/1995	Namavar et al.	6,236,872	B1	5/2001	Diab et al.
D361,840	S	8/1995	Savage et al.	6,241,683	B1	6/2001	Macklem et al.
D362,063	S	9/1995	Savage et al.	6,253,097	B1	6/2001	Aronow et al.
5,452,717	A	9/1995	Branigan et al.	6,255,708	B1	7/2001	Sudharsanan et al.
D363,120	S	10/1995	Savage et al.	6,256,523	B1	7/2001	Diab et al.
5,456,252	A	10/1995	Vari et al.	6,263,222	B1	7/2001	Diab et al.
5,479,934	A	1/1996	Imran	6,278,522	B1	8/2001	Lepper, Jr. et al.
5,482,036	A	1/1996	Diab et al.	6,280,213	B1	8/2001	Tobler et al.
5,490,505	A	2/1996	Diab et al.	6,280,381	B1	8/2001	Malin et al.
5,494,043	A	2/1996	O'Sullivan et al.	6,285,896	B1	9/2001	Tobler et al.
5,533,511	A	7/1996	Kaspari et al.	6,301,493	B1	10/2001	Marro et al.
5,534,851	A	7/1996	Russek	6,308,089	B1	10/2001	von der Ruhr et al.
5,561,275	A	10/1996	Savage et al.	6,317,627	B1	11/2001	Ennen et al.
5,562,002	A	10/1996	Lalin	6,321,100	B1	11/2001	Parker
5,590,649	A	1/1997	Caro et al.	6,325,761	B1	12/2001	Jay
5,602,924	A	2/1997	Durand et al.	6,334,065	B1	12/2001	Al-Ali et al.
5,632,272	A	5/1997	Diab et al.	6,343,224	B1	1/2002	Parker
5,638,816	A	6/1997	Kiani-Azarbayjany et al.	6,349,228	B1	2/2002	Kiani et al.
5,638,818	A	6/1997	Diab et al.	6,360,114	B1	3/2002	Diab et al.
5,645,440	A	7/1997	Tobler et al.	6,366,805	B1	4/2002	Lutz
5,671,914	A	9/1997	Kalkhoran et al.	6,368,283	B1	4/2002	Xu et al.
5,685,299	A	11/1997	Diab et al.	6,371,921	B1	4/2002	Caro et al.
5,699,808	A *	12/1997	John A61B 5/4821 600/483	6,377,829	B1	4/2002	Al-Ali
5,726,440	A	3/1998	Kalkhoran et al.	6,388,240	B2	5/2002	Schulz et al.
D393,830	S	4/1998	Tobler et al.	6,397,091	B2	5/2002	Diab et al.
5,743,262	A	4/1998	Lepper, Jr. et al.	6,411,373	B1	6/2002	Garside et al.
5,747,806	A	5/1998	Khalil et al.	6,415,167	B1	7/2002	Blank et al.
5,750,994	A	5/1998	Schlager	6,430,437	B1	8/2002	Marro
5,758,644	A	6/1998	Diab et al.	6,430,525	B1	8/2002	Weber et al.
5,760,910	A	6/1998	Lepper, Jr. et al.	6,463,311	B1	10/2002	Diab
5,769,785	A	6/1998	Diab et al.	6,470,199	B1	10/2002	Kopotic et al.
5,782,757	A	7/1998	Diab et al.	6,487,429	B2	11/2002	Hockersmith et al.
5,785,659	A	7/1998	Caro et al.	6,501,975	B2	12/2002	Diab et al.
5,791,347	A	8/1998	Flaherty et al.	6,505,059	B1	1/2003	Kollias et al.
5,810,734	A	9/1998	Caro et al.	6,515,273	B2	2/2003	Al-Ali
5,823,950	A	10/1998	Diab et al.	6,519,487	B1	2/2003	Parker
5,830,131	A	11/1998	Caro et al.	6,525,386	B1	2/2003	Mills et al.
5,833,618	A	11/1998	Caro et al.	6,526,300	B1	2/2003	Kiani et al.
5,860,919	A	1/1999	Kiani-Azarbayjany et al.	6,534,012	B1	3/2003	Hazen et al.
5,890,929	A	4/1999	Mills et al.	6,541,756	B2	4/2003	Schulz et al.
5,904,654	A	5/1999	Wohlmann et al.	6,542,764	B1	4/2003	Al-Ali et al.
5,919,134	A	7/1999	Diab	6,580,086	B1	6/2003	Schulz et al.
5,934,925	A	8/1999	Tobler et al.	6,584,336	B1	6/2003	Ali et al.
5,940,182	A	8/1999	Lepper, Jr. et al.	6,587,196	B1	7/2003	Stippick et al.
5,987,343	A	11/1999	Kinast	6,587,199	B1	7/2003	Luu
5,995,855	A	11/1999	Kiani et al.	6,595,316	B2	7/2003	Cybulski et al.
5,997,343	A	12/1999	Mills et al.	6,597,932	B2	7/2003	Tian et al.
6,002,952	A	12/1999	Diab et al.	6,597,933	B2	7/2003	Kiani et al.
6,010,937	A	1/2000	Karam et al.	6,606,511	B1	8/2003	Ali et al.
6,011,986	A	1/2000	Diab et al.	6,632,181	B2	10/2003	Flaherty et al.
6,016,444	A	1/2000	John	6,635,559	B2	10/2003	Greenwald et al.
6,016,449	A	1/2000	Fischell et al.	6,639,668	B1	10/2003	Trepagnier
6,027,452	A	2/2000	Flaherty et al.	6,640,116	B2	10/2003	Diab
6,036,642	A	3/2000	Diab et al.	6,640,117	B2	10/2003	Makarewicz et al.
6,040,578	A	3/2000	Malin et al.	6,643,530	B2	11/2003	Diab et al.
6,045,509	A	4/2000	Caro et al.	6,650,917	B2	11/2003	Diab et al.
6,066,204	A	5/2000	Haven	6,654,624	B2	11/2003	Diab et al.
6,067,462	A	5/2000	Diab et al.	6,654,626	B2	11/2003	Devlin et al.
6,081,735	A	6/2000	Diab et al.	6,658,276	B2	12/2003	Kiani et al.
6,088,607	A	7/2000	Diab et al.	6,661,161	B1	12/2003	Lanzo et al.
6,110,522	A	8/2000	Lepper, Jr. et al.	6,671,531	B2	12/2003	Al-Ali et al.
6,115,673	A	9/2000	Malin et al.	6,678,543	B2	1/2004	Diab et al.
6,124,597	A	9/2000	Shehada	6,684,090	B2	1/2004	Ali et al.
				6,684,091	B2	1/2004	Parker
				6,697,164	B1	2/2004	Babayoff et al.
				6,697,656	B1	2/2004	Al-Ali
				6,697,657	B1	2/2004	Shehada et al.
				6,697,658	B2	2/2004	Al-Ali

(56)

References Cited

U.S. PATENT DOCUMENTS

RE38,476 E	3/2004	Diab et al.	7,245,953 B1	7/2007	Parker
6,699,194 B1	3/2004	Diab et al.	7,254,429 B2	8/2007	Schurman et al.
6,714,804 B2	3/2004	Al-Ali et al.	7,254,431 B2	8/2007	Al-Ali
RE38,492 E	4/2004	Diab et al.	7,254,433 B2	8/2007	Diab et al.
6,721,582 B2	4/2004	Trepagnier et al.	7,254,434 B2	8/2007	Schulz et al.
6,721,585 B1	4/2004	Parker	7,272,425 B2	9/2007	Al-Ali
6,725,075 B2	4/2004	Al-Ali	7,274,955 B2	9/2007	Kiani et al.
6,728,560 B2	4/2004	Kollias et al.	D554,263 S	10/2007	Al-Ali
6,735,459 B2	5/2004	Parker	7,280,550 B1	10/2007	Rosenboom
6,738,652 B2	5/2004	Mattu et al.	7,280,858 B2	10/2007	Al-Ali et al.
6,745,060 B2	6/2004	Diab et al.	7,289,835 B2	10/2007	Mansfield et al.
6,760,607 B2	7/2004	Al-Ali	7,292,883 B2	11/2007	De Felice et al.
6,770,028 B1	8/2004	Ali et al.	7,295,866 B2	11/2007	Al-Ali
6,771,994 B2	8/2004	Kiani et al.	7,308,894 B2	12/2007	Hickle
6,788,965 B2	9/2004	Ruchti et al.	7,328,053 B1	2/2008	Diab et al.
6,792,300 B1	9/2004	Diab et al.	7,332,784 B2	2/2008	Mills et al.
6,813,511 B2	11/2004	Diab et al.	7,340,287 B2	3/2008	Mason et al.
6,816,241 B2	11/2004	Grubisic	7,341,559 B2	3/2008	Schulz et al.
6,816,741 B2	11/2004	Diab	7,341,599 B1	3/2008	Peyman
6,822,564 B2	11/2004	Al-Ali	7,343,186 B2	3/2008	Lamego et al.
6,826,419 B2	11/2004	Diab et al.	D566,282 S	4/2008	Al-Ali et al.
6,830,711 B2	12/2004	Mills et al.	7,355,512 B1	4/2008	Al-Ali
6,850,787 B2	2/2005	Weber et al.	7,356,365 B2	4/2008	Schurman
6,850,788 B2	2/2005	Al-Ali	7,371,981 B2	5/2008	Abdul-Hafiz
6,852,083 B2	2/2005	Caro et al.	7,373,193 B2	5/2008	Al-Ali et al.
6,861,639 B2	3/2005	Al-Ali	7,373,194 B2	5/2008	Weber et al.
6,876,931 B2	4/2005	Lorenz et al.	7,376,453 B1	5/2008	Diab et al.
6,898,452 B2	5/2005	Al-Ali et al.	7,377,794 B2	5/2008	Al Ali et al.
6,920,345 B2	7/2005	Al-Ali et al.	7,377,899 B2	5/2008	Weber et al.
6,931,268 B1	8/2005	Kiani-Azarbayjany et al.	7,383,070 B2	6/2008	Diab et al.
6,934,570 B2	8/2005	Kiani et al.	7,395,158 B2	7/2008	Monfre et al.
6,939,305 B2	9/2005	Flaherty et al.	7,415,297 B2	8/2008	Al-Ali et al.
6,943,348 B1	9/2005	Coffin, IV	7,428,432 B2	9/2008	Ali et al.
6,944,501 B1	9/2005	Pless	7,438,683 B2	10/2008	Al-Ali et al.
6,950,687 B2	9/2005	Al-Ali	7,440,787 B2	10/2008	Diab
6,956,649 B2	10/2005	Acosta et al.	7,454,240 B2	11/2008	Diab et al.
6,961,598 B2	11/2005	Diab	7,467,002 B2	12/2008	Weber et al.
6,970,792 B1	11/2005	Diab	7,469,157 B2	12/2008	Diab et al.
6,979,812 B2	12/2005	Al-Ali	7,471,969 B2	12/2008	Diab et al.
6,985,764 B2	1/2006	Mason et al.	7,471,971 B2	12/2008	Diab et al.
6,990,364 B2	1/2006	Ruchti et al.	7,483,729 B2	1/2009	Al-Ali et al.
6,993,371 B2	1/2006	Kiani et al.	7,483,730 B2	1/2009	Diab et al.
6,996,427 B2	2/2006	Ali et al.	7,489,958 B2	2/2009	Diab et al.
6,998,247 B2	2/2006	Monfre et al.	7,496,391 B2	2/2009	Diab et al.
6,999,904 B2	2/2006	Weber et al.	7,496,393 B2	2/2009	Diab et al.
7,003,338 B2	2/2006	Weber et al.	D587,657 S	3/2009	Al-Ali et al.
7,003,339 B2	2/2006	Diab et al.	7,499,741 B2	3/2009	Diab et al.
7,015,451 B2	3/2006	Dalke et al.	7,499,835 B2	3/2009	Weber et al.
7,024,233 B2	4/2006	Ali et al.	7,500,950 B2	3/2009	Al-Ali et al.
7,027,849 B2	4/2006	Al-Ali	7,509,154 B2	3/2009	Diab et al.
7,030,749 B2	4/2006	Al-Ali	7,509,494 B2	3/2009	Al-Ali
7,039,449 B2	5/2006	Al-Ali	7,510,849 B2	3/2009	Schurman et al.
7,041,060 B2	5/2006	Flaherty et al.	7,514,725 B2	4/2009	Wojtczuk et al.
7,044,918 B2	5/2006	Diab	7,519,406 B2	4/2009	Blank et al.
7,047,054 B2	5/2006	Benni	7,526,328 B2	4/2009	Diab et al.
7,048,687 B1	5/2006	Reuss et al.	D592,507 S	5/2009	Wachman et al.
7,067,893 B2	6/2006	Mills et al.	7,530,942 B1	5/2009	Diab
7,072,701 B2	7/2006	Chen et al.	7,530,949 B2	5/2009	Al Ali et al.
D526,719 S	8/2006	Richie, Jr. et al.	7,530,955 B2	5/2009	Diab et al.
7,096,052 B2	8/2006	Mason et al.	7,563,110 B2	7/2009	Al-Ali et al.
7,096,054 B2	8/2006	Abdul-Hafiz et al.	7,593,230 B2	9/2009	Abul-Haj et al.
D529,616 S	10/2006	Deros et al.	7,596,398 B2	9/2009	Al-Ali et al.
7,132,641 B2	11/2006	Schulz et al.	7,606,608 B2	10/2009	Blank et al.
7,133,710 B2	11/2006	Acosta et al.	7,618,375 B2	11/2009	Flaherty
7,142,901 B2	11/2006	Kiani et al.	7,620,674 B2	11/2009	Ruchti et al.
7,149,561 B2	12/2006	Diab	D606,659 S	12/2009	Kiani et al.
7,186,966 B2	3/2007	Al-Ali	7,629,039 B2	12/2009	Eckerbom et al.
7,190,261 B2	3/2007	Al-Ali	7,640,140 B2	12/2009	Ruchti et al.
7,215,984 B2	5/2007	Diab	7,647,083 B2	1/2010	Al-Ali et al.
7,215,986 B2	5/2007	Diab	D609,193 S	2/2010	Al-Ali et al.
7,221,971 B2	5/2007	Diab	D614,305 S	4/2010	Al-Ali et al.
7,225,006 B2	5/2007	Al-Ali et al.	7,697,966 B2	4/2010	Monfire et al.
7,225,007 B2	5/2007	Al-Ali	7,698,105 B2	4/2010	Ruchti et al.
RE39,672 E	6/2007	Shehada et al.	RE41,317 E	5/2010	Parker
7,239,905 B2	7/2007	Kiani-Azarbayjany et al.	RE41,333 E	5/2010	Blank et al.
			7,729,733 B2	6/2010	Al-Ali et al.
			7,734,320 B2	6/2010	Al-Ali
			7,761,127 B2	7/2010	Al-Ali et al.
			7,761,128 B2	7/2010	Al-Ali et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

7,761,146 B2	7/2010	Carlson et al.	8,274,360 B2	9/2012	Sampath et al.
7,764,982 B2	7/2010	Dalke et al.	8,280,473 B2	10/2012	Al-Ali
D621,516 S	8/2010	Kiani et al.	8,301,217 B2	10/2012	Al-Ali et al.
7,791,155 B2	9/2010	Diab	8,306,596 B2	11/2012	Schurman et al.
7,801,581 B2	9/2010	Diab	8,310,336 B2	11/2012	Muhsin et al.
7,822,452 B2	10/2010	Schurman et al.	8,315,683 B2	11/2012	Al-Ali et al.
RE41,912 E	11/2010	Parker	RE43,860 E	12/2012	Parker
7,844,313 B2	11/2010	Kiani et al.	8,337,403 B2	12/2012	Al-Ali et al.
7,844,314 B2	11/2010	Al-Ali	8,346,330 B2	1/2013	Lamego
7,844,315 B2	11/2010	Al-Ali	8,353,842 B2	1/2013	Al-Ali et al.
7,865,222 B2	1/2011	Weber et al.	8,355,766 B2	1/2013	MacNeish, III et al.
7,873,497 B2	1/2011	Weber et al.	8,359,080 B2	1/2013	Diab et al.
7,880,606 B2	2/2011	Al-Ali	8,364,223 B2	1/2013	Al-Ali et al.
7,880,626 B2	2/2011	Al-Ali et al.	8,364,226 B2	1/2013	Diab et al.
7,891,355 B2	2/2011	Al-Ali et al.	8,374,665 B2	2/2013	Lamego
7,894,868 B2	2/2011	Al-Ali et al.	8,385,995 B2	2/2013	Al-Ali et al.
7,899,507 B2	3/2011	Al-Ali et al.	8,385,996 B2	2/2013	Smith et al.
7,899,518 B2	3/2011	Trepagnier et al.	8,388,353 B2	3/2013	Kiani et al.
7,904,132 B2	3/2011	Weber et al.	8,399,822 B2	3/2013	Al-Ali
7,909,772 B2	3/2011	Popov et al.	8,401,602 B2	3/2013	Kiani
7,910,875 B2	3/2011	Al-Ali	8,405,608 B2	3/2013	Al-Ali et al.
7,919,713 B2	4/2011	Al-Ali et al.	8,414,499 B2	4/2013	Al-Ali et al.
7,937,128 B2	5/2011	Al-Ali	8,418,524 B2	4/2013	Al-Ali
7,937,129 B2	5/2011	Mason et al.	8,423,106 B2	4/2013	Lamego et al.
7,937,130 B2	5/2011	Diab et al.	8,428,967 B2	4/2013	Olsen et al.
7,941,199 B2	5/2011	Kiani	8,430,817 B1	4/2013	Al-Ali et al.
7,951,086 B2	5/2011	Flaherty et al.	8,437,825 B2	5/2013	Dalvi et al.
7,957,780 B2	6/2011	Lamego et al.	8,455,290 B2	6/2013	Siskavich
7,962,188 B2	6/2011	Kiani et al.	8,457,703 B2	6/2013	Al-Ali
7,962,190 B1	6/2011	Diab et al.	8,457,707 B2	6/2013	Kiani
7,976,472 B2	7/2011	Kiani	8,463,349 B2	6/2013	Diab et al.
7,988,637 B2	8/2011	Diab	8,466,286 B2	6/2013	Bellot et al.
7,990,382 B2	8/2011	Kiani	8,471,713 B2	6/2013	Poeze et al.
7,991,446 B2	8/2011	Al-Ali et al.	8,473,020 B2	6/2013	Kiani et al.
8,000,761 B2	8/2011	Al-Ali	8,483,787 B2	7/2013	Al-Ali et al.
8,008,088 B2	8/2011	Bellott et al.	8,489,364 B2	7/2013	Weber et al.
RE42,753 E	9/2011	Kiani-Azarbayjany et al.	8,498,684 B2	7/2013	Weber et al.
8,019,400 B2	9/2011	Diab et al.	8,504,128 B2	8/2013	Blank et al.
8,028,701 B2	10/2011	Al-Ali et al.	8,509,867 B2	8/2013	Workman et al.
8,029,765 B2	10/2011	Bellott et al.	8,515,509 B2	8/2013	Bruinsma et al.
8,036,727 B2	10/2011	Schurman et al.	8,523,781 B2	9/2013	Al-Ali
8,036,728 B2	10/2011	Diab et al.	8,529,301 B2	9/2013	Al-Ali et al.
8,046,040 B2	10/2011	Ali et al.	8,532,727 B2	9/2013	Ali et al.
8,046,041 B2	10/2011	Diab et al.	8,532,728 B2	9/2013	Diab et al.
8,046,042 B2	10/2011	Diab et al.	D692,145 S	10/2013	Al-Ali et al.
8,048,040 B2	11/2011	Kiani	8,547,209 B2	10/2013	Kiani et al.
8,050,728 B2	11/2011	Al-Ali et al.	8,548,548 B2	10/2013	Al-Ali
RE43,169 E	2/2012	Parker	8,548,549 B2	10/2013	Schurman et al.
8,118,620 B2	2/2012	Al-Ali et al.	8,548,550 B2	10/2013	Al-Ali et al.
8,126,528 B2	2/2012	Diab et al.	8,560,032 B2	10/2013	Al-Ali et al.
8,128,572 B2	3/2012	Diab et al.	8,560,034 B1	10/2013	Diab et al.
8,130,105 B2	3/2012	Al-Ali et al.	8,570,167 B2	10/2013	Al-Ali
8,145,287 B2	3/2012	Diab et al.	8,570,503 B2	10/2013	Vo et al.
8,150,487 B2	4/2012	Diab et al.	8,571,617 B2	10/2013	Reichgott et al.
8,175,672 B2	5/2012	Parker	8,571,618 B1	10/2013	Lamego et al.
8,180,420 B2	5/2012	Diab et al.	8,571,619 B2	10/2013	Al-Ali et al.
8,182,443 B1	5/2012	Kiani	8,577,431 B2	11/2013	Lamego et al.
8,185,180 B2	5/2012	Diab et al.	8,581,732 B2	11/2013	Al-Ali et al.
8,190,223 B2	5/2012	Al-Ali et al.	8,584,345 B2	11/2013	Al-Ali et al.
8,190,227 B2	5/2012	Diab et al.	8,588,880 B2	11/2013	Abdul-Hafiz et al.
8,203,438 B2	6/2012	Kiani et al.	8,600,467 B2	12/2013	Al-Ali et al.
8,203,704 B2	6/2012	Merritt et al.	8,606,342 B2	12/2013	Diab
8,204,566 B2	6/2012	Schurman et al.	8,626,255 B2	1/2014	Al-Ali et al.
8,219,172 B2	7/2012	Schurman et al.	8,630,691 B2	1/2014	Lamego et al.
8,224,411 B2	7/2012	Al-Ali et al.	8,634,889 B2	1/2014	Al-Ali et al.
8,228,181 B2	7/2012	Al-Ali	8,641,631 B2	2/2014	Sierra et al.
8,229,532 B2	7/2012	Davis	8,652,060 B2	2/2014	Al-Ali
8,229,533 B2	7/2012	Diab et al.	8,663,107 B2	3/2014	Kiani
8,233,955 B2	7/2012	Al-Ali et al.	8,666,468 B1	3/2014	Al-Ali
8,244,325 B2	8/2012	Al-Ali et al.	8,667,967 B2	3/2014	Al-Ali et al.
8,255,026 B1	8/2012	Al-Ali	8,670,811 B2	3/2014	O'Reilly
8,255,027 B2	8/2012	Al-Ali et al.	8,670,814 B2	3/2014	Diab et al.
8,255,028 B2	8/2012	Al-Ali et al.	8,676,286 B2	3/2014	Weber et al.
8,260,577 B2	9/2012	Weber et al.	8,682,407 B2	3/2014	Al-Ali
8,265,723 B1	9/2012	McHale et al.	RE44,823 E	4/2014	Parker
			RE44,875 E	4/2014	Kiani et al.
			8,688,183 B2	4/2014	Bruinsma et al.
			8,690,799 B2	4/2014	Telfort et al.
			8,700,112 B2	4/2014	Kiani

(56)

References Cited

U.S. PATENT DOCUMENTS

8,702,627	B2	4/2014	Telfort et al.	9,131,882	B2	9/2015	Al-Ali et al.
8,706,179	B2	4/2014	Parker	9,131,883	B2	9/2015	Al-Ali
8,712,494	B1	4/2014	MacNeish, III et al.	9,131,917	B2	9/2015	Telfort et al.
8,715,206	B2	5/2014	Telfort et al.	9,138,180	B1	9/2015	Coverston et al.
8,718,735	B2	5/2014	Lamego et al.	9,138,182	B2	9/2015	Al-Ali et al.
8,718,737	B2	5/2014	Diab et al.	9,138,192	B2	9/2015	Weber et al.
8,718,738	B2	5/2014	Blank et al.	9,142,117	B2	9/2015	Muhsin et al.
8,720,249	B2	5/2014	Al-Ali	9,153,112	B1	10/2015	Kiani et al.
8,721,541	B2	5/2014	Al-Ali et al.	9,153,121	B2	10/2015	Kiani et al.
8,721,542	B2	5/2014	Al-Ali et al.	9,161,696	B2	10/2015	Al-Ali et al.
8,723,677	B1	5/2014	Kiani	9,161,713	B2	10/2015	Al-Ali et al.
8,740,792	B1	6/2014	Kiani et al.	9,167,995	B2	10/2015	Lamego et al.
8,754,776	B2	6/2014	Poeze et al.	9,176,141	B2	11/2015	Al-Ali et al.
8,755,535	B2	6/2014	Telfort et al.	9,186,102	B2	11/2015	Bruinsma et al.
8,755,856	B2	6/2014	Diab et al.	9,192,312	B2	11/2015	Al-Ali
8,755,872	B1	6/2014	Marinow	9,192,329	B2	11/2015	Al-Ali
8,761,850	B2	6/2014	Lamego	9,192,330	B2	11/2015	Lin
8,764,671	B2	7/2014	Kiani	9,192,351	B1	11/2015	Telfort et al.
8,768,423	B2	7/2014	Shakespeare et al.	9,195,385	B2	11/2015	Al-Ali et al.
8,771,204	B2	7/2014	Telfort et al.	9,211,072	B2	12/2015	Kiani
8,777,634	B2	7/2014	Kiani et al.	9,211,095	B1	12/2015	Al-Ali
8,781,543	B2	7/2014	Diab et al.	9,218,454	B2	12/2015	Kiani et al.
8,781,544	B2	7/2014	Al-Ali et al.	9,226,696	B2	1/2016	Kiani
8,781,549	B2	7/2014	Al-Ali et al.	9,241,662	B2	1/2016	Al-Ali et al.
8,788,003	B2	7/2014	Schurman et al.	9,245,668	B1	1/2016	Vo et al.
8,790,268	B2	7/2014	Al-Ali	9,259,185	B2	2/2016	Abdul-Hafiz et al.
8,801,613	B2	8/2014	Al-Ali et al.	9,267,572	B2	2/2016	Barker et al.
8,821,397	B2	9/2014	Al-Ali et al.	9,277,880	B2	3/2016	Poeze et al.
8,821,415	B2	9/2014	Al-Ali et al.	9,289,167	B2	3/2016	Diab et al.
8,830,449	B1	9/2014	Lamego et al.	9,295,421	B2	3/2016	Kiani et al.
8,831,700	B2	9/2014	Schurman et al.	9,307,928	B1	4/2016	Al-Ali et al.
8,840,549	B2	9/2014	Al-Ali et al.	9,323,894	B2	4/2016	Kiani
8,847,740	B2	9/2014	Kiani et al.	D755,392	S	5/2016	Hwang et al.
8,849,365	B2	9/2014	Smith et al.	9,326,712	B1	5/2016	Kiani
8,852,094	B2	10/2014	Al-Ali et al.	9,333,316	B2	5/2016	Kiani
8,852,994	B2	10/2014	Wojtczuk et al.	9,339,220	B2	5/2016	Lamego et al.
8,868,147	B2	10/2014	Stippick et al.	9,341,565	B2	5/2016	Lamego et al.
8,868,150	B2	10/2014	Al-Ali et al.	9,351,673	B2	5/2016	Diab et al.
8,870,792	B2	10/2014	Al-Ali et al.	9,351,675	B2	5/2016	Al-Ali et al.
8,886,271	B2	11/2014	Kiani et al.	9,364,181	B2	6/2016	Kiani et al.
8,888,539	B2	11/2014	Al-Ali et al.	9,368,671	B2	6/2016	Wojtczuk et al.
8,888,708	B2	11/2014	Diab et al.	9,370,325	B2	6/2016	Al-Ali et al.
8,892,180	B2	11/2014	Weber et al.	9,370,326	B2	6/2016	McHale et al.
8,897,847	B2	11/2014	Al-Ali	9,370,335	B2	6/2016	Al-Ali et al.
8,909,310	B2	12/2014	Lamego et al.	9,375,185	B2	6/2016	Ali et al.
8,911,377	B2	12/2014	Al-Ali	9,386,953	B2	7/2016	Al-Ali
8,912,909	B2	12/2014	Al-Ali et al.	9,386,961	B2	7/2016	Al-Ali et al.
8,920,317	B2	12/2014	Al-Ali et al.	9,392,945	B2	7/2016	Al-Ali et al.
8,921,699	B2	12/2014	Al-Ali et al.	9,397,448	B2	7/2016	Al-Ali et al.
8,922,382	B2	12/2014	Al-Ali et al.	9,408,542	B1	8/2016	Kinast et al.
8,929,964	B2	1/2015	Al-Ali et al.	9,436,645	B2	9/2016	Al-Ali et al.
8,942,777	B2	1/2015	Diab et al.	9,445,759	B1	9/2016	Lamego et al.
8,948,834	B2	2/2015	Diab et al.	9,466,919	B2	10/2016	Kiani et al.
8,948,835	B2	2/2015	Diab	9,474,474	B2	10/2016	Lamego et al.
8,965,471	B2	2/2015	Lamego	9,480,422	B2	11/2016	Al-Ali
8,983,564	B2	3/2015	Al-Ali	9,480,435	B2	11/2016	Olsen
8,989,831	B2	3/2015	Al-Ali et al.	9,492,110	B2	11/2016	Al-Ali et al.
8,996,085	B2	3/2015	Kiani et al.	9,510,779	B2	12/2016	Poeze et al.
8,998,809	B2	4/2015	Kiani	9,517,024	B2	12/2016	Kiani et al.
9,028,429	B2	5/2015	Telfort et al.	9,532,722	B2	1/2017	Lamego et al.
9,037,207	B2	5/2015	Al-Ali et al.	9,538,949	B2	1/2017	Al-Ali et al.
9,060,721	B2	6/2015	Reichgott et al.	9,538,980	B2	1/2017	Telfort et al.
9,066,666	B2	6/2015	Kiani	9,549,696	B2	1/2017	Lamego et al.
9,066,680	B1	6/2015	Al-Ali et al.	9,554,737	B2	1/2017	Schurman et al.
9,072,474	B2	7/2015	Al-Ali et al.	9,560,996	B2	2/2017	Kiani
9,078,560	B2	7/2015	Schurman et al.	9,560,998	B2	2/2017	Al-Ali et al.
9,084,569	B2	7/2015	Weber et al.	9,566,019	B2	2/2017	Al-Ali et al.
9,095,316	B2	8/2015	Welch et al.	9,579,039	B2	2/2017	Jansen et al.
9,106,038	B2	8/2015	Telfort et al.	9,591,975	B2	3/2017	Dalvi et al.
9,107,625	B2	8/2015	Telfort et al.	9,622,692	B2	4/2017	Lamego et al.
9,107,626	B2	8/2015	Al-Ali et al.	9,622,693	B2	4/2017	Diab
9,113,831	B2	8/2015	Al-Ali	D788,312	S	5/2017	Al-Ali et al.
9,113,832	B2	8/2015	Al-Ali	9,636,055	B2	5/2017	Al-Ali et al.
9,119,595	B2	9/2015	Lamego	9,636,056	B2	5/2017	Al-Ali
9,131,881	B2	9/2015	Diab et al.	9,649,054	B2	5/2017	Lamego et al.
				9,662,052	B2	5/2017	Al-Ali et al.
				9,668,679	B2	6/2017	Schurman et al.
				9,668,680	B2	6/2017	Bruinsma et al.
				9,668,703	B2	6/2017	Al-Ali

(56)

References Cited

U.S. PATENT DOCUMENTS

9,675,286 B2	6/2017	Diab	10,058,275 B2	8/2018	Al-Ali et al.
9,687,160 B2	6/2017	Kiani	10,064,562 B2	9/2018	Al-Ali
9,693,719 B2	7/2017	Al-Ali et al.	10,086,138 B1	10/2018	Novak, Jr.
9,693,737 B2	7/2017	Al-Ali	10,092,200 B2	10/2018	Al-Ali et al.
9,697,928 B2	7/2017	Al-Ali et al.	10,092,249 B2	10/2018	Kiani et al.
9,712,318 B2	7/2017	Foerester et al.	10,098,550 B2	10/2018	Al-Ali et al.
9,717,425 B2	8/2017	Kiani et al.	10,098,591 B2	10/2018	Al-Ali et al.
9,717,458 B2	8/2017	Lamego et al.	10,098,610 B2	10/2018	Al-Ali et al.
9,724,016 B1	8/2017	Al-Ali et al.	10,111,591 B2	10/2018	Dyell et al.
9,724,024 B2	8/2017	Al-Ali	D833,624 S	11/2018	DeJong et al.
9,724,025 B1	8/2017	Kiani et al.	10,123,726 B2	11/2018	Al-Ali et al.
9,730,640 B2	8/2017	Diab et al.	10,123,729 B2	11/2018	Dyell et al.
9,743,887 B2	8/2017	Al-Ali et al.	10,130,289 B2	11/2018	Al-Ali et al.
9,749,232 B2	8/2017	Sampath et al.	10,130,291 B2	11/2018	Schurman et al.
9,750,442 B2	9/2017	Olsen	D835,282 S	12/2018	Barker et al.
9,750,443 B2	9/2017	Smith et al.	D835,283 S	12/2018	Barker et al.
9,750,461 B1	9/2017	Telfort	D835,284 S	12/2018	Barker et al.
9,775,545 B2	10/2017	Al-Ali et al.	D835,285 S	12/2018	Barker et al.
9,775,546 B2	10/2017	Diab et al.	10,149,616 B2	12/2018	Al-Ali et al.
9,775,570 B2	10/2017	Al-Ali	10,154,815 B2	12/2018	Al-Ali et al.
9,778,079 B1	10/2017	Al-Ali et al.	10,159,412 B2	12/2018	Lamego et al.
9,782,077 B2	10/2017	Lamego et al.	10,188,296 B2	1/2019	Al-Ali et al.
9,782,110 B2	10/2017	Kiani	10,188,331 B1	1/2019	Al-Ali et al.
9,787,568 B2	10/2017	Lamego et al.	10,188,348 B2	1/2019	Kiani et al.
9,788,735 B2	10/2017	Al-Ali	RE47,218 E	2/2019	Al-Ali
9,788,768 B2	10/2017	Al-Ali et al.	RE47,244 E	2/2019	Kiani et al.
9,795,300 B2	10/2017	Al-Ali	RE47,249 E	2/2019	Kiani et al.
9,795,310 B2	10/2017	Al-Ali	10,194,847 B2	2/2019	Al-Ali
9,795,358 B2	10/2017	Telfort et al.	10,194,848 B1	2/2019	Kiani et al.
9,795,739 B2	10/2017	Al-Ali et al.	10,201,298 B2	2/2019	Al-Ali et al.
9,801,556 B2	10/2017	Kiani	10,205,272 B2	2/2019	Kiani et al.
9,801,588 B2	10/2017	Weber et al.	10,205,291 B2	2/2019	Scruggs et al.
9,808,188 B1	11/2017	Perea et al.	10,213,108 B2	2/2019	Al-Ali
9,814,418 B2	11/2017	Weber et al.	10,219,706 B2	3/2019	Al-Ali
9,820,691 B2	11/2017	Kiani	10,219,746 B2	3/2019	McHale et al.
9,833,152 B2	12/2017	Kiani et al.	10,226,187 B2	3/2019	Al-Ali et al.
9,833,180 B2	12/2017	Shakespeare et al.	10,226,576 B2	3/2019	Kiani
9,839,379 B2	12/2017	Al-Ali et al.	10,231,657 B2	3/2019	Al-Ali et al.
9,839,381 B1	12/2017	Weber et al.	10,231,670 B2	3/2019	Blank et al.
9,847,002 B2	12/2017	Kiani et al.	10,231,676 B2	3/2019	Al-Ali et al.
9,847,749 B2	12/2017	Kiani et al.	RE47,353 E	4/2019	Kiani et al.
9,848,800 B1	12/2017	Lee et al.	10,251,585 B2	4/2019	Al-Ali et al.
9,848,806 B2	12/2017	Al-Ali et al.	10,251,586 B2	4/2019	Lamego
9,848,807 B2	12/2017	Lamego	10,255,994 B2	4/2019	Sampath et al.
9,861,298 B2	1/2018	Eckerbom et al.	10,258,265 B1	4/2019	Poeze et al.
9,861,304 B2	1/2018	Al-Ali et al.	10,258,266 B1	4/2019	Poeze et al.
9,861,305 B1	1/2018	Weber et al.	10,271,748 B2	4/2019	Al-Ali
9,867,578 B2	1/2018	Al-Ali et al.	10,278,626 B2	5/2019	Schurman et al.
9,872,623 B2	1/2018	Al-Ali	10,278,648 B2	5/2019	Al-Ali et al.
9,876,320 B2	1/2018	Coverston et al.	10,279,247 B2	5/2019	Kiani
9,877,650 B2	1/2018	Muhsin et al.	10,292,628 B1	5/2019	Poeze et al.
9,877,686 B2	1/2018	Al-Ali et al.	10,292,657 B2	5/2019	Abdul-Hafiz et al.
9,891,079 B2	2/2018	Dalvi	10,292,664 B2	5/2019	Al-Ali
9,895,107 B2	2/2018	Al-Ali et al.	10,299,708 B1	5/2019	Poeze et al.
9,913,617 B2	3/2018	Al-Ali et al.	10,299,709 B2	5/2019	Perea et al.
9,924,893 B2	3/2018	Schurman et al.	10,299,720 B2	5/2019	Brown et al.
9,924,897 B1	3/2018	Abdul-Hafiz	10,305,775 B2	5/2019	Lamego et al.
9,936,917 B2	4/2018	Poeze et al.	10,307,111 B2	6/2019	Muhsin et al.
9,943,269 B2	4/2018	Muhsin et al.	10,325,681 B2	6/2019	Sampath et al.
9,949,676 B2	4/2018	Al-Ali	10,327,337 B2	6/2019	Triman et al.
9,955,937 B2	5/2018	Telfort	10,327,713 B2	6/2019	Barker et al.
9,965,946 B2	5/2018	Al-Ali	10,332,630 B2	6/2019	Al-Ali
9,980,667 B2	5/2018	Kiani et al.	10,383,520 B2	8/2019	Wojtczuk et al.
D820,865 S	6/2018	Muhsin et al.	10,383,527 B2	8/2019	Al-Ali
9,986,919 B2	6/2018	Lamego et al.	10,388,120 B2	8/2019	Muhsin et al.
9,986,952 B2	6/2018	Dalvi et al.	D864,120 S	10/2019	Forrest et al.
9,989,560 B2	6/2018	Poeze et al.	10,441,181 B1	10/2019	Telfort et al.
9,993,207 B2	6/2018	Al-Ali et al.	10,441,196 B2	10/2019	Eckerbom et al.
10,007,758 B2	6/2018	Al-Ali et al.	10,448,844 B2	10/2019	Al-Ali et al.
D822,215 S	7/2018	Al-Ali et al.	10,448,871 B2	10/2019	Al-Ali et al.
D822,216 S	7/2018	Barker et al.	10,456,038 B2	10/2019	Lamego et al.
10,010,276 B2	7/2018	Al-Ali et al.	10,463,340 B2	11/2019	Telfort et al.
10,032,002 B2	7/2018	Kiani et al.	10,471,159 B1	11/2019	Lapotko et al.
10,039,482 B2	8/2018	Al-Ali et al.	10,505,311 B2	12/2019	Al-Ali et al.
10,052,037 B2	8/2018	Kinast et al.	10,524,738 B2	1/2020	Olsen
			10,532,174 B2	1/2020	Al-Ali
			10,537,285 B2	1/2020	Shreim et al.
			10,542,903 B2	1/2020	Al-Ali et al.
			10,555,678 B2	2/2020	Dalvi et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

10,568,553 B2	2/2020	O'Neil et al.	11,504,066 B1	11/2022	Dalvi et al.
RE47,882 E	3/2020	Al-Ali	D971,933 S	12/2022	Ahmed
10,608,817 B2	3/2020	Haider et al.	D973,072 S	12/2022	Ahmed
D880,477 S	4/2020	Forrest et al.	D973,685 S	12/2022	Ahmed
10,617,302 B2	4/2020	Al-Ali et al.	D973,686 S	12/2022	Ahmed
10,617,335 B2	4/2020	Al-Ali et al.	D974,193 S	1/2023	Forrest et al.
10,637,181 B2	4/2020	Al-Ali et al.	D979,516 S	2/2023	Al-Ali et al.
D886,849 S	6/2020	Muhsin et al.	D980,091 S	3/2023	Forrest et al.
D887,548 S	6/2020	Abdul-Hafiz et al.	11,596,363 B2	3/2023	Lamego
D887,549 S	6/2020	Abdul-Hafiz et al.	11,627,919 B2	4/2023	Kiani et al.
10,667,764 B2	6/2020	Ahmed et al.	11,637,437 B2	4/2023	Al-Ali et al.
D890,708 S	7/2020	Forrest et al.	D985,498 S	5/2023	Al-Ali et al.
10,721,785 B2	7/2020	Al-Ali	11,653,862 B2	5/2023	Dalvi et al.
10,736,518 B2	8/2020	Al-Ali et al.	D989,112 S	6/2023	Muhsin et al.
10,750,984 B2	8/2020	Pauley et al.	D989,327 S	6/2023	Al-Ali et al.
D897,098 S	9/2020	Al-Ali	11,678,829 B2	6/2023	Al-Ali et al.
10,779,098 B2	9/2020	Iswanto et al.	11,679,579 B2	6/2023	Al-Ali
10,827,961 B1	11/2020	Iyengar et al.	11,684,296 B2	6/2023	Vo et al.
10,828,007 B1	11/2020	Telfort et al.	11,692,934 B2	7/2023	Normand et al.
10,832,818 B2	11/2020	Muhsin et al.	11,701,043 B2	7/2023	Al-Ali et al.
10,849,554 B2	12/2020	Shreim et al.	D997,365 S	8/2023	Hwang
10,856,750 B2	12/2020	Indorf et al.	11,721,105 B2	8/2023	Ranasinghe et al.
D906,970 S	1/2021	Forrest et al.	11,730,379 B2	8/2023	Ahmed et al.
D908,213 S	1/2021	Abdul-Hafiz et al.	D998,625 S	9/2023	Indorf et al.
10,918,281 B2	2/2021	Al-Ali et al.	D998,630 S	9/2023	Indorf et al.
10,932,705 B2	3/2021	Muhsin et al.	D998,631 S	9/2023	Indorf et al.
10,932,729 B2	3/2021	Kiani et al.	D999,244 S	9/2023	Indorf et al.
10,939,878 B2	3/2021	Kiani et al.	D999,245 S	9/2023	Indorf et al.
10,956,950 B2	3/2021	Al-Ali et al.	D999,246 S	9/2023	Indorf et al.
D916,135 S	4/2021	Indorf et al.	11,766,198 B2	9/2023	Pauley et al.
D917,046 S	4/2021	Abdul-Hafiz et al.	D1,000,975 S	10/2023	Al-Ali et al.
D917,550 S	4/2021	Indorf et al.	11,803,623 B2	10/2023	Kiani et al.
D917,564 S	4/2021	Indorf et al.	11,832,940 B2	12/2023	Diab et al.
D917,704 S	4/2021	Al-Ali et al.	D1,013,179 S	1/2024	Al-Ali et al.
10,987,066 B2	4/2021	Chandran et al.	11,872,156 B2	1/2024	Telfort et al.
10,991,135 B2	4/2021	Al-Ali et al.	11,879,960 B2	1/2024	Ranasinghe et al.
D919,094 S	5/2021	Al-Ali et al.	11,883,129 B2	1/2024	Olsen
D919,100 S	5/2021	Al-Ali et al.	D1,022,729 S	4/2024	Forrest et al.
11,006,867 B2	5/2021	Al-Ali	11,951,186 B2	4/2024	Krishnamani et al.
D921,202 S	6/2021	Al-Ali et al.	11,974,833 B2	5/2024	Forrest et al.
11,024,064 B2	6/2021	Muhsin et al.	11,986,067 B2	5/2024	Al-Ali et al.
11,026,604 B2	6/2021	Chen et al.	11,986,289 B2	5/2024	Dalvi et al.
D925,597 S	7/2021	Chandran et al.	11,986,305 B2	5/2024	Al-Ali et al.
D927,699 S	8/2021	Al-Ali et al.	D1,031,729 S	6/2024	Forrest et al.
11,076,777 B2	8/2021	Lee et al.	12,004,869 B2	6/2024	Kiani et al.
11,114,188 B2	9/2021	Poeze et al.	12,014,328 B2	6/2024	Wachman et al.
D933,232 S	10/2021	Al-Ali et al.	D1,036,293 S	7/2024	Al-Ali et al.
D933,233 S	10/2021	Al-Ali et al.	D1,037,462 S	7/2024	Al-Ali et al.
D933,234 S	10/2021	Al-Ali et al.	12,029,844 B2	7/2024	Pauley et al.
11,145,408 B2	10/2021	Sampath et al.	12,048,534 B2	7/2024	Vo et al.
11,147,518 B1	10/2021	Al-Ali et al.	12,064,217 B2	8/2024	Ahmed et al.
11,185,262 B2	11/2021	Al-Ali et al.	12,066,426 B1	8/2024	Lapotko et al.
11,191,484 B2	12/2021	Kiani et al.	D1,041,511 S	9/2024	Indorf et al.
D946,596 S	3/2022	Ahmed	D1,042,596 S	9/2024	DeJong et al.
D946,597 S	3/2022	Ahmed	D1,042,852 S	9/2024	Hwang
D946,598 S	3/2022	Ahmed	12,076,159 B2	9/2024	Belur Nagaraj et al.
D946,617 S	3/2022	Ahmed	12,082,926 B2	9/2024	Sharma et al.
11,272,839 B2	3/2022	Al-Ali et al.	D1,044,828 S	10/2024	Chandran et al.
11,289,199 B2	3/2022	Al-Ali	D1,048,571 S	10/2024	Yu et al.
RE49,034 E	4/2022	Al-Ali	D1,048,908 S	10/2024	Al-Ali et al.
11,298,021 B2	4/2022	Muhsin et al.	12,106,752 B2	10/2024	Campbell et al.
D950,580 S	5/2022	Ahmed	12,114,974 B2	10/2024	Al-Ali et al.
D950,599 S	5/2022	Ahmed	12,126,683 B2	10/2024	Koo et al.
D950,738 S	5/2022	Al-Ali et al.	12,127,838 B2	10/2024	Olsen et al.
D957,648 S	7/2022	Al-Ali	12,128,213 B2	10/2024	Kiani et al.
11,382,567 B2	7/2022	O'Brien et al.	12,131,661 B2	10/2024	Pauley et al.
11,389,093 B2	7/2022	Triman et al.	D1,050,910 S	11/2024	Al-Ali et al.
11,406,286 B2	8/2022	Al-Ali et al.	12,178,572 B1	12/2024	Pauley et al.
11,417,426 B2	8/2022	Muhsin et al.	12,178,581 B2	12/2024	Telfort et al.
11,439,329 B2	9/2022	Lamego	12,178,852 B2	12/2024	Kiani et al.
11,445,948 B2	9/2022	Scruggs et al.	D1,057,159 S	1/2025	DeJong et al.
D965,789 S	10/2022	Al-Ali et al.	D1,057,160 S	1/2025	DeJong et al.
D967,433 S	10/2022	Al-Ali et al.	12,198,790 B1	1/2025	Al-Ali
11,464,410 B2	10/2022	Muhsin	12,200,421 B2	1/2025	Campbell et al.
11,504,058 B1	11/2022	Sharma et al.	12,207,901 B1	1/2025	Lapotko et al.
			D1,060,680 S	2/2025	Al-Ali et al.
			D1,063,893 S	2/2025	DeJong et al.
			12,235,941 B2	2/2025	Kiani et al.
			12,236,767 B2	2/2025	Muhsin

(56)	References Cited			2009/0095926	A1	4/2009	MacNeish, III
	U.S. PATENT DOCUMENTS			2009/0131762	A1	5/2009	Pelzek et al.
				2009/0149148	A1*	6/2009	Kurtz G06K 9/00536 455/307
	D1,066,244	S	3/2025	Lim et al.		6/2009	Kim
	D1,066,672	S	3/2025	Al-Ali et al.		8/2009	Chow A61K 31/137 514/1.1
	2001/0034477	A1	10/2001	Mansfield et al.		10/2009	Lamego et al.
	2001/0039483	A1	11/2001	Brand et al.		11/2009	Davis
	2002/0010401	A1	1/2002	Bushmakina et al.		11/2009	Al-Ali
	2002/0058864	A1	5/2002	Mansfield et al.		12/2009	Wang A61B 5/14539 348/68
	2002/0059159	A1*	5/2002	Cook A61B 5/4094 706/62			
	2002/0117176	A1*	8/2002	Mantzaris A61B 5/1106 128/204.23		1/2010	Vo et al.
	2002/0133080	A1	9/2002	Apruzzese et al.		2/2010	Poeze et al.
	2002/0173729	A1*	11/2002	Viertio-Oja A61B 5/374 600/544		4/2010	O'Reilly et al.
	2003/0013975	A1	1/2003	Kiani		9/2010	Sampath et al.
	2003/0018243	A1	1/2003	Gerhardt et al.		10/2010	Wachman et al.
	2003/0055355	A1*	3/2003	Viertio-Oja A61B 5/16 600/544		12/2010	Hargrove et al.
	2003/0144582	A1	7/2003	Cohen et al.		2/2011	Merritt et al.
	2003/0145854	A1*	8/2003	Hickle G16H 40/63 128/204.18		2/2011	Goodman
	2003/0156288	A1	8/2003	Barnum et al.		2/2011	Welch et al.
	2003/0212312	A1	11/2003	Coffin, IV et al.		3/2011	Derchak
	2004/0038169	A1	2/2004	Mandelkern et al.		4/2011	Poeze et al.
	2004/0073415	A1*	4/2004	Farhat G06N 3/02 703/2		4/2011	Kiani et al.
	2004/0106163	A1	6/2004	Workman, Jr. et al.		5/2011	Chen G06T 3/40 375/240.16
	2004/0193068	A1*	9/2004	Burton A61B 5/4812 600/544		5/2011	Tari et al.
	2005/0007091	A1*	1/2005	Makeig A61B 5/374 324/76.13		5/2011	Telfort A61B 7/003 600/586
	2005/0010116	A1*	1/2005	Korhonen A61B 5/4035 600/481		6/2011	Kiani et al.
	2005/0055276	A1	3/2005	Kiani et al.		7/2011	Olsen et al.
	2005/0124863	A1*	6/2005	Cook A61B 5/4094 600/300		7/2011	Hulin
	2005/0124888	A1*	6/2005	Jjt Rein A61B 8/0833 600/443		8/2011	Welch et al.
	2005/0234317	A1	10/2005	Kiani		9/2011	Al-Ali
	2006/0062432	A1*	3/2006	Watanabe G08G 1/163 382/104		11/2011	O'Brien
	2006/0073719	A1	4/2006	Kiani		2/2012	Sugio H04N 5/23296 348/135
	2006/0149160	A1*	7/2006	Kofol A61B 5/369 600/544		3/2012	Chamoun et al.
	2006/0161054	A1	7/2006	Reuss et al.		4/2012	Al-Ali et al.
	2006/0189871	A1	8/2006	Al-Ali et al.		5/2012	O'Reilly
	2007/0010756	A1*	1/2007	Viertio-Oja G16H 50/50 600/544		6/2012	Merritt et al.
	2007/0055114	A1*	3/2007	Viertio-Oja A61B 5/389 600/300		8/2012	McLaughlin A61B 5/4094 600/301
	2007/0073116	A1	3/2007	Kiani et al.			
	2007/0116119	A1*	5/2007	Wang H04N 19/51 375/240.12		8/2012	McKenna A61B 5/4821 600/322
	2007/0150025	A1*	6/2007	Dilorenzo A61B 5/4094 607/45		8/2012	Al-Ali
	2007/0180140	A1	8/2007	Welch et al.		8/2012	Olsen et al.
	2007/0208322	A1	9/2007	Rantala et al.		9/2012	Lamego et al.
	2007/0244377	A1	10/2007	Cozad et al.		11/2012	Burton A61B 5/02405 600/301
	2007/0282478	A1	12/2007	Al-Ali et al.			
	2008/0064965	A1	3/2008	Jay et al.		11/2012	Kiani et al.
	2008/0094228	A1	4/2008	Welch et al.		1/2013	Lamego et al.
	2008/0103375	A1	5/2008	Kiani		2/2013	Lamego
	2008/0107307	A1*	5/2008	Altherr H04N 5/23248 382/107		3/2013	Welch et al.
	2008/0117968	A1*	5/2008	Wang H04N 19/61 375/240.12		4/2013	Garfio
	2008/0204566	A1*	8/2008	Yamazaki G03B 5/00 348/208.99		4/2013	Sampath et al.
	2008/0221418	A1	9/2008	Al-Ali et al.		6/2013	Jensen
	2008/0234598	A1*	9/2008	Snyder A61B 5/374 600/545		8/2013	Bardakjian A61B 5/291 600/383
	2009/0036759	A1	2/2009	Ault et al.			
	2009/0093687	A1*	4/2009	Telfort A61B 5/318 600/300			
				2009/0095926	A1	4/2009	MacNeish, III
				2009/0131762	A1	5/2009	Pelzek et al.
				2009/0149148	A1*	6/2009	Kurtz G06K 9/00536 455/307
				2009/0160642	A1	6/2009	Kim
				2009/0198145	A1*	8/2009	Chow A61K 31/137 514/1.1
				2009/0247984	A1	10/2009	Lamego et al.
				2009/0275813	A1	11/2009	Davis
				2009/0275844	A1	11/2009	Al-Ali
				2009/0322865	A1*	12/2009	Wang A61B 5/14539 348/68
				2010/0004518	A1	1/2010	Vo et al.
				2010/0030040	A1	2/2010	Poeze et al.
				2010/0099964	A1	4/2010	O'Reilly et al.
				2010/0220180	A1*	9/2010	Lee A61B 5/073 348/74
				2010/0234718	A1	9/2010	Sampath et al.
				2010/0270257	A1	10/2010	Wachman et al.
				2010/0324441	A1	12/2010	Hargrove et al.
				2011/0028806	A1	2/2011	Merritt et al.
				2011/0028809	A1	2/2011	Goodman
				2011/0040197	A1	2/2011	Welch et al.
				2011/0054272	A1	3/2011	Derchak
				2011/0082711	A1	4/2011	Poeze et al.
				2011/0087081	A1	4/2011	Kiani et al.
				2011/0116547	A1*	5/2011	Chen G06T 3/40 375/240.16
				2011/0118561	A1	5/2011	Tari et al.
				2011/0125060	A1*	5/2011	Telfort A61B 7/003 600/586
				2011/0137297	A1	6/2011	Kiani et al.
				2011/0172498	A1	7/2011	Olsen et al.
				2011/0184307	A1	7/2011	Hulin
				2011/0208015	A1	8/2011	Welch et al.
				2011/0230733	A1	9/2011	Al-Ali
				2011/0270047	A1	11/2011	O'Brien
				2012/0044347	A1*	2/2012	Sugio H04N 5/23296 348/135
				2012/0053433	A1	3/2012	Chamoun et al.
				2012/0083673	A1	4/2012	Al-Ali et al.
				2012/0123231	A1	5/2012	O'Reilly
				2012/0165629	A1	6/2012	Merritt et al.
				2012/0203079	A1*	8/2012	McLaughlin A61B 5/4094 600/301
				2012/0203087	A1*	8/2012	McKenna A61B 5/4821 600/322
				2012/0209082	A1	8/2012	Al-Ali
				2012/0209084	A1	8/2012	Olsen et al.
				2012/0226117	A1	9/2012	Lamego et al.
				2012/0277548	A1*	11/2012	Burton A61B 5/02405 600/301
				2012/0283524	A1	11/2012	Kiani et al.
				2013/0023775	A1	1/2013	Lamego et al.
				2013/0041591	A1	2/2013	Lamego
				2013/0060147	A1	3/2013	Welch et al.
				2013/0096405	A1	4/2013	Garfio
				2013/0096936	A1	4/2013	Sampath et al.
				2013/0150748	A1	6/2013	Jensen
				2013/0197339	A1*	8/2013	Bardakjian A61B 5/291 600/383
				2013/0243021	A1	9/2013	Siskavich
				2013/0253334	A1	9/2013	Al-Ali et al.
				2013/0276785	A1	10/2013	Melker et al.
				2013/0296672	A1	11/2013	O'Neil et al.
				2013/0296713	A1	11/2013	Al-Ali et al.
				2013/0324808	A1	12/2013	Al-Ali et al.
				2013/0331660	A1	12/2013	Al-Ali et al.
				2013/0345921	A1	12/2013	Al-Ali et al.
				2014/0012100	A1	1/2014	Al-Ali et al.
				2014/0051953	A1	2/2014	Lamego et al.
				2014/0120564	A1	5/2014	Workman et al.
				2014/0121482	A1	5/2014	Merritt et al.
				2014/0127137	A1	5/2014	Bellott et al.
				2014/0163344	A1	6/2014	Al-Ali
				2014/0166076	A1	6/2014	Kiani et al.
				2014/0171763	A1	6/2014	Diab
				2014/0180038	A1	6/2014	Kiani

(56)

References Cited

U.S. PATENT DOCUMENTS

2014/0180154	A1	6/2014	Sierra et al.		2017/0007198	A1	1/2017	Al-Ali et al.
2014/0180160	A1	6/2014	Brown et al.		2017/0014083	A1	1/2017	Diab et al.
2014/0187973	A1 *	7/2014	Brown	G16H 50/20 600/483	2017/0014084	A1	1/2017	Al-Ali et al.
2014/0213864	A1	7/2014	Abdul-Hafiz et al.		2017/0024748	A1	1/2017	Haider
2014/0275835	A1	9/2014	Lamego et al.		2017/0042488	A1	2/2017	Muhsin
2014/0275871	A1	9/2014	Lamego et al.		2017/0055851	A1	3/2017	Al-Ali
2014/0275872	A1	9/2014	Merritt et al.		2017/0055882	A1	3/2017	Al-Ali et al.
2014/0288400	A1	9/2014	Diab et al.		2017/0055887	A1	3/2017	Al-Ali
2014/0316217	A1	10/2014	Purdon et al.		2017/0055896	A1	3/2017	Al-Ali et al.
2014/0316218	A1	10/2014	Purdon et al.		2017/0079594	A1	3/2017	Telfort et al.
2014/0316228	A1	10/2014	Blank et al.		2017/0086723	A1	3/2017	Al-Ali et al.
2014/0323825	A1	10/2014	Al-Ali et al.		2017/0143281	A1	5/2017	Olsen
2014/0323897	A1	10/2014	Brown et al.		2017/0147774	A1	5/2017	Kiani
2014/0323898	A1	10/2014	Purdon et al.		2017/0156620	A1	6/2017	Al-Ali et al.
2014/0330092	A1	11/2014	Al-Ali et al.		2017/0173632	A1	6/2017	Al-Ali
2014/0330098	A1	11/2014	Merritt et al.		2017/0181693	A1	6/2017	Kim et al.
2014/0357966	A1	12/2014	Al-Ali et al.		2017/0187146	A1	6/2017	Kiani et al.
2015/0005600	A1	1/2015	Blank et al.		2017/0188919	A1	7/2017	Al-Ali et al.
2015/0011907	A1	1/2015	Purdon et al.		2017/0196464	A1	7/2017	Jansen et al.
2015/0032029	A1	1/2015	Al-Ali et al.		2017/0196470	A1	7/2017	Lamego et al.
2015/0038859	A1	2/2015	Dalvi et al.		2017/0224262	A1	8/2017	Al-Ali
2015/0073241	A1	3/2015	Lamego		2017/0228516	A1	8/2017	Sampath et al.
2015/0080754	A1	3/2015	Purdon et al.		2017/0245790	A1	8/2017	Al-Ali et al.
2015/0087936	A1	3/2015	Al-Ali et al.		2017/0251974	A1	9/2017	Shreim et al.
2015/0094546	A1	4/2015	Al-Ali		2017/0251975	A1	9/2017	Shreim et al.
2015/0099950	A1	4/2015	Al-Ali et al.		2017/0258403	A1	9/2017	Abdul-Hafiz et al.
2015/0101844	A1	4/2015	Al-Ali et al.		2017/0311851	A1	11/2017	Schurman et al.
2015/0106121	A1	4/2015	Muhsin et al.		2017/0311891	A1	11/2017	Kiani et al.
2015/0112151	A1	4/2015	Muhsin et al.		2017/0325728	A1	11/2017	Al-Ali et al.
2015/0142082	A1	5/2015	Simon et al.		2017/0332976	A1	11/2017	Al-Ali et al.
2015/0165312	A1	6/2015	Kiani		2017/0340293	A1	11/2017	Al-Ali et al.
2015/0196249	A1	7/2015	Brown et al.		2017/0360310	A1	12/2017	Kiani et al.
2015/0216459	A1	8/2015	Al-Ali et al.		2017/0367632	A1	12/2017	Al-Ali et al.
2015/0238722	A1	8/2015	Al-Ali		2018/0008146	A1	1/2018	Al-Ali et al.
2015/0245773	A1	9/2015	Lamego et al.		2018/0013562	A1	1/2018	Haider et al.
2015/0245794	A1	9/2015	Al-Ali		2018/0014752	A1	1/2018	Al-Ali et al.
2015/0257689	A1	9/2015	Al-Ali et al.		2018/0028124	A1	2/2018	Al-Ali et al.
2015/0272508	A1	10/2015	Chiouchang et al.		2018/0055385	A1	3/2018	Al-Ali
2015/0272514	A1	10/2015	Kiani et al.		2018/0055390	A1	3/2018	Kiani et al.
2015/0306390	A1 *	10/2015	Zalay	A61N 1/36064 607/45	2018/0055430	A1	3/2018	Diab et al.
2015/0351697	A1	12/2015	Weber et al.		2018/0064381	A1	3/2018	Shakespeare et al.
2015/0359429	A1	12/2015	Al-Ali et al.		2018/0069776	A1	3/2018	Lamego et al.
2015/0366507	A1	12/2015	Blank		2018/0070867	A1	3/2018	Smith et al.
2016/0029932	A1	2/2016	Al-Ali		2018/0082767	A1	3/2018	Al-Ali et al.
2016/0058347	A1	3/2016	Reichgott et al.		2018/0085068	A1	3/2018	Telfort
2016/0066824	A1	3/2016	Al-Ali et al.		2018/0087937	A1	3/2018	Al-Ali et al.
2016/0081552	A1	3/2016	Wojtczuk et al.		2018/0103874	A1	4/2018	Lee et al.
2016/0095543	A1	4/2016	Telfort et al.		2018/0103905	A1	4/2018	Kiani
2016/0095548	A1	4/2016	Al-Ali et al.		2018/0110478	A1	4/2018	Al-Ali
2016/0103598	A1	4/2016	Al-Ali et al.		2018/0116575	A1	5/2018	Perea et al.
2016/0166182	A1	6/2016	Al-Ali et al.		2018/0125368	A1	5/2018	Lamego et al.
2016/0166183	A1	6/2016	Poeze et al.		2018/0125430	A1	5/2018	Al-Ali et al.
2016/0196388	A1	7/2016	Lamego		2018/0125445	A1	5/2018	Telfort et al.
2016/0197436	A1	7/2016	Barker et al.		2018/0130325	A1	5/2018	Kiani et al.
2016/0213281	A1	7/2016	Eckerbom et al.		2018/0132769	A1	5/2018	Weber et al.
2016/0228043	A1	8/2016	O'Neil et al.		2018/0132770	A1	5/2018	Lamego
2016/0233632	A1	8/2016	Scruggs et al.		2018/0146901	A1	5/2018	Al-Ali et al.
2016/0234944	A1	8/2016	Schmidt et al.		2018/0146902	A1	5/2018	Kiani et al.
2016/0270735	A1	9/2016	Diab et al.		2018/0153442	A1	6/2018	Eckerbom et al.
2016/0283665	A1	9/2016	Sampath et al.		2018/0153446	A1	6/2018	Kiani
2016/0287090	A1	10/2016	Al-Ali et al.		2018/0153447	A1	6/2018	Al-Ali et al.
2016/0287162	A1 *	10/2016	Bardakjian	A61B 5/291	2018/0153448	A1	6/2018	Weber et al.
2016/0287786	A1	10/2016	Kiani		2018/0161499	A1	6/2018	Al-Ali et al.
2016/0296169	A1	10/2016	McHale et al.		2018/0168491	A1	6/2018	Al-Ali et al.
2016/0310052	A1	10/2016	Al-Ali et al.		2018/0174679	A1	6/2018	Sampath et al.
2016/0314260	A1	10/2016	Kiani		2018/0174680	A1	6/2018	Sampath et al.
2016/0324446	A1 *	11/2016	Prerau	A61B 5/0533	2018/0182484	A1	6/2018	Sampath et al.
2016/0324488	A1	11/2016	Olsen		2018/0184917	A1	7/2018	Kiani
2016/0327984	A1	11/2016	Al-Ali et al.		2018/0192924	A1	7/2018	Al-Ali
2016/0331332	A1	11/2016	Al-Ali		2018/0192953	A1	7/2018	Shreim et al.
2016/0367173	A1	12/2016	Dalvi et al.		2018/0192955	A1	7/2018	Al-Ali et al.
2017/0000394	A1	1/2017	Al-Ali et al.		2018/0199871	A1	7/2018	Pauley et al.
2017/0007134	A1	1/2017	Al-Ali et al.		2018/0206795	A1	7/2018	Al-Ali
					2018/0206815	A1	7/2018	Telfort
					2018/0213583	A1	7/2018	Al-Ali
					2018/0214031	A1	8/2018	Kiani et al.
					2018/0214090	A1	8/2018	Al-Ali et al.
					2018/0218792	A1	8/2018	Muhsin et al.
					2018/0225960	A1	8/2018	Al-Ali et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

2018/0238718	A1	8/2018	Dalvi	2020/0253544	A1	8/2020	Belur Nagaraj et al.
2018/0242853	A1	8/2018	Al-Ali	2020/0275841	A1	9/2020	Telfort et al.
2018/0242921	A1	8/2018	Muhsin et al.	2020/0288983	A1	9/2020	Telfort et al.
2018/0242923	A1	8/2018	Al-Ali et al.	2020/0321793	A1	10/2020	Al-Ali et al.
2018/0242924	A1	8/2018	Barker et al.	2020/0329983	A1	10/2020	Al-Ali et al.
2018/0242926	A1	8/2018	Muhsin et al.	2020/0329984	A1	10/2020	Al-Ali et al.
2018/0247353	A1	8/2018	Al-Ali et al.	2020/0329993	A1	10/2020	Al-Ali et al.
2018/0247712	A1	8/2018	Muhsin et al.	2020/0330037	A1	10/2020	Al-Ali et al.
2018/0249933	A1	9/2018	Schurman et al.	2021/0022628	A1	1/2021	Telfort et al.
2018/0253947	A1	9/2018	Muhsin et al.	2021/0041953	A1*	2/2021	Poltorak A61B 5/0077
2018/0256087	A1	9/2018	Al-Ali et al.	2021/0104173	A1	4/2021	Pauley et al.
2018/0256113	A1	9/2018	Weber et al.	2021/0113121	A1	4/2021	Diab et al.
2018/0285094	A1	10/2018	Housel et al.	2021/0117525	A1	4/2021	Kiani et al.
2018/0289325	A1	10/2018	Poeze et al.	2021/0118581	A1	4/2021	Kiani et al.
2018/0289337	A1	10/2018	Al-Ali et al.	2021/0121582	A1	4/2021	Krishnamani et al.
2018/0296161	A1	10/2018	Shreim et al.	2021/0161465	A1	6/2021	Barker et al.
2018/0300919	A1	10/2018	Muhsin et al.	2021/0236729	A1	8/2021	Kiani et al.
2018/0310822	A1	11/2018	Indorf et al.	2021/0256267	A1	8/2021	Ranasinghe et al.
2018/0310823	A1	11/2018	Al-Ali et al.	2021/0256835	A1	8/2021	Ranasinghe et al.
2018/0317826	A1	11/2018	Muhsin	2021/0275101	A1	9/2021	Vo et al.
2018/0317841	A1	11/2018	Novak, Jr.	2021/0290060	A1	9/2021	Ahmed
2018/0333055	A1	11/2018	Lamego et al.	2021/0290072	A1	9/2021	Forrest
2018/0333087	A1	11/2018	Al-Ali	2021/0290080	A1	9/2021	Ahmed
2019/0000317	A1	1/2019	Muhsin et al.	2021/0290120	A1	9/2021	Al-Ali
2019/0000362	A1	1/2019	Kiani et al.	2021/0290177	A1	9/2021	Novak, Jr.
2019/0015023	A1	1/2019	Monfre	2021/0290184	A1	9/2021	Ahmed
2019/0021638	A1	1/2019	Al-Ali et al.	2021/0296008	A1	9/2021	Novak, Jr.
2019/0029574	A1	1/2019	Schurman et al.	2021/0330228	A1	10/2021	Olsen et al.
2019/0029578	A1	1/2019	Al-Ali et al.	2021/0386382	A1	12/2021	Olsen et al.
2019/0038143	A1	2/2019	Al-Ali	2021/0402110	A1	12/2021	Pauley et al.
2019/0058280	A1	2/2019	Al-Ali et al.	2022/0039707	A1	2/2022	Sharma et al.
2019/0058281	A1	2/2019	Al-Ali et al.	2022/0053892	A1	2/2022	Al-Ali et al.
2019/0069813	A1	3/2019	Al-Ali	2022/0071562	A1	3/2022	Kiani
2019/0069814	A1	3/2019	Al-Ali	2022/0096603	A1	3/2022	Kiani et al.
2019/0076028	A1	3/2019	Al-Ali et al.	2022/0151521	A1	5/2022	Krishnamani et al.
2019/0082979	A1	3/2019	Al-Ali et al.	2022/0218244	A1	7/2022	Kiani et al.
2019/0090748	A1	3/2019	Al-Ali	2022/0287574	A1	9/2022	Telfort et al.
2019/0090760	A1	3/2019	Kinast et al.	2022/0296161	A1	9/2022	Al-Ali et al.
2019/0090764	A1	3/2019	Al-Ali	2022/0361819	A1	11/2022	Al-Ali et al.
2019/0104973	A1	4/2019	Poeze et al.	2022/0379059	A1	12/2022	Yu et al.
2019/0110719	A1	4/2019	Poeze et al.	2022/0392610	A1	12/2022	Kiani et al.
2019/0117070	A1	4/2019	Muhsin et al.	2023/0028745	A1	1/2023	Al-Ali
2019/0117139	A1	4/2019	Al-Ali et al.	2023/0038389	A1	2/2023	Vo
2019/0117140	A1	4/2019	Al-Ali et al.	2023/0045647	A1	2/2023	Vo
2019/0117141	A1	4/2019	Al-Ali	2023/0058052	A1	2/2023	Al-Ali
2019/0117930	A1	4/2019	Al-Ali	2023/0058342	A1	2/2023	Kiani
2019/0122763	A1	4/2019	Sampath et al.	2023/0069789	A1	3/2023	Koo et al.
2019/0133525	A1	5/2019	Al-Ali et al.	2023/0087671	A1	3/2023	Telfort et al.
2019/0142283	A1	5/2019	Lamego et al.	2023/0110152	A1	4/2023	Forrest et al.
2019/0142344	A1	5/2019	Telfort et al.	2023/0111198	A1	4/2023	Yu et al.
2019/0150800	A1	5/2019	Poeze et al.	2023/0115397	A1	4/2023	Vo et al.
2019/0150856	A1	5/2019	Kiani et al.	2023/0116371	A1	4/2023	Mills et al.
2019/0167161	A1	6/2019	Al-Ali et al.	2023/0135297	A1	5/2023	Kiani et al.
2019/0175019	A1	6/2019	Al-Ali et al.	2023/0138098	A1	5/2023	Telfort et al.
2019/0192076	A1	6/2019	McHale et al.	2023/0145155	A1	5/2023	Krishnamani et al.
2019/0200941	A1	7/2019	Chandran et al.	2023/0147750	A1	5/2023	Barker et al.
2019/0239787	A1	8/2019	Pauley et al.	2023/0210417	A1	7/2023	Al-Ali et al.
2019/0320906	A1	10/2019	Olsen	2023/0222805	A1	7/2023	Muhsin et al.
2019/0320988	A1	10/2019	Ahmed et al.	2023/0222887	A1	7/2023	Muhsin et al.
2019/0374139	A1	12/2019	Kiani et al.	2023/0226331	A1	7/2023	Kiani et al.
2019/0374173	A1	12/2019	Kiani et al.	2023/0284916	A1	9/2023	Telfort
2019/0374713	A1	12/2019	Kiani et al.	2023/0284943	A1	9/2023	Scruggs et al.
2020/0021930	A1	1/2020	Iswanto et al.	2023/0301562	A1	9/2023	Scruggs et al.
2020/0060869	A1	2/2020	Telfort et al.	2023/0346993	A1	11/2023	Kiani et al.
2020/0111552	A1	4/2020	Ahmed	2023/0368221	A1	11/2023	Haider
2020/0113435	A1	4/2020	Muhsin	2023/0371893	A1	11/2023	Al-Ali et al.
2020/0113488	A1	4/2020	Al-Ali et al.	2023/0389837	A1	12/2023	Krishnamani et al.
2020/0113496	A1	4/2020	Scruggs et al.	2024/0016418	A1	1/2024	Devadoss et al.
2020/0113497	A1	4/2020	Triman et al.	2024/0016419	A1	1/2024	Devadoss et al.
2020/0113520	A1	4/2020	Abdul-Hafiz et al.	2024/0047061	A1	2/2024	Al-Ali et al.
2020/0138288	A1	5/2020	Al-Ali et al.	2024/0049310	A1	2/2024	Al-Ali et al.
2020/0138368	A1	5/2020	Kiani et al.	2024/0049986	A1	2/2024	Al-Ali et al.
2020/0163597	A1	5/2020	Dalvi et al.	2024/0081656	A1	3/2024	DeJong et al.
2020/0196877	A1	6/2020	Vo et al.	2024/0122486	A1	4/2024	Kiani
2020/0253474	A1	8/2020	Muhsin et al.	2024/0180456	A1	6/2024	Al-Ali
				2024/0188872	A1	6/2024	Al-Ali et al.
				2024/0245855	A1	7/2024	Vo et al.
				2024/0260894	A1	8/2024	Olsen
				2024/0267698	A1	8/2024	Telfort et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

2024/0277233	A1	8/2024	Al-Ali
2024/0277280	A1	8/2024	Al-Ali
2024/0298920	A1	9/2024	Fernkbist et al.
2024/0306985	A1	9/2024	Vo et al.
2024/0324953	A1	10/2024	Telfort
2024/0380246	A1	11/2024	Moran
2024/0380247	A1	11/2024	Moran
2024/0404549	A1	12/2024	Campbell et al.
2025/0000458	A1	1/2025	Abdul-Hafiz et al.

OTHER PUBLICATIONS

Ionescu et al., C. M., Variable Time-Delay Estimation for Anesthesia Control During Intensive Care, IEEE Transactions on Biomedical Engineering, Feb. 1, 2011, pp. 363-369, vol. 58, No. 2, IEEE Service Center, Piscataway, NJ, USA.

International Search Report and Written Opinion received in PCT Application No. PCT/US2013/044598, dated Sep. 25, 2013.

Letter from Tara A. Ryan to Masimo Corporation re 510(k) No. K172890, U.S. Food & Drug Administration, dated Jan. 26, 2018 in 9 pages.

Letter from Todd D. Courtney to Masimo Corporation re 510(k) No. K203113, U.S. Food & Drug Administration, dated Feb. 25, 2022.

* cited by examiner




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6






FIG. 7

*FIG. 8*

*FIG. 9*




FIG. 10




FIG. 11




FIG. 12





FIG. 13






FIG. 15




FIG. 16

DEPTH OF CONSCIOUSNESS MONITOR**CROSS REFERENCE TO RELATED APPLICATIONS**

This application is a divisional of U.S. application Ser. No. 13/911,939, filed Jun. 6, 2013, now U.S. Pat. No. 10,542,903, which claims the benefit of priority from U.S. Provisional No. 61/703,747, filed Sep. 20, 2012, and U.S. Provisional No. 61/656,974, filed Jun. 7, 2012, all of which are incorporated by reference in their entireties.

FIELD OF THE DISCLOSURE

The present disclosure relates to the field of patient monitoring. In some embodiments, the disclosure relates to monitoring the depth of consciousness of a patient under anesthetic sedation.

BACKGROUND

General anesthesia is often used to put patients to sleep and block pain and memory during medical or diagnostic procedures. While extremely useful, general anesthesia is not risk free. Caregivers therefore generally seek to maintain a depth of consciousness consistent with the needs of a particular medical procedure. Caregivers will monitor various physiological parameters of the patient to predict the patient's depth of consciousness. In response to monitored parameters, the caregiver may manually adjust the anesthetic dosage level to avoid over and under dosing. However, as a patient's depth of consciousness may frequently change, caregivers often employ a host of monitoring technologies to attempt to periodically, sporadically, or continually ascertain the wellness and consciousness of a patient. For example, caregivers may desire to monitor one or more of a patient's temperature, electroencephalogram or EEG, brain oxygen saturation, stimulus response, electromyography or EMG, respiration, body oxygen saturation or other blood analytes, pulse, hydration, blood pressure, perfusion, or other parameters or combinations of parameters. For many of the foregoing, monitoring technologies are individually readily available and widely used, such as, for example, pulse oximeters, vital signs monitors, and the like.

In their depth of consciousness monitoring, caregivers may also use recording devices to acquire EEG signals. For example, caregivers place electrodes on the skin of the forehead to detect electrical activity produced by the firing of neurons within the brain. From patterns in the electrical activity, caregivers attempt to determine, among other things, the state of consciousness of the brain. Caregivers may also use a pulse oximeter or cerebral oximetry to determine the percentage of oxygenation of the hemoglobin in the patient's blood. Caregivers may also use an EMG monitor to detect the muscular action and mechanical impulses generated by the musculature around the patient's forehead, among other bodily locations. Caregivers manually monitor such physiological parameters and then manually adjust anesthetic dosage.

However, manual monitoring and dosage adjustment could lead to serious adverse results, including death, if improperly performed. In addition, typical depth of consciousness monitors do not account for variations in responses to sedation therapies that exist between patient demographics. Furthermore, typical depth of consciousness monitors do not account for differences in physiological responses that exists between particular sedation therapies

and among different patient populations. Therefore, there remains a need in the art for a depth of consciousness monitor that is configured to automatically communicate with a caregiver and/or an anesthetic dosage device to provide accurate control over patient care by accounting for variations between populations and drug actions.

SUMMARY

Based on at least the foregoing, the present disclosure seeks to overcome some or all of the drawbacks discussed above and provide additional advantages over prior technologies. The present disclosure describes embodiments of noninvasive methods, devices, and systems for monitoring depth of consciousness through brain electrical activity.

In one embodiment, a depth of consciousness monitor is configured to determine the level of sedation of a medical patient. The depth of consciousness monitor includes: an EEG interface configured to receive an EEG signal from an EEG sensor; an EEG front end configured to pre-process the EEG signal; a processor, configured to determine a level of sedation of a medical patient based at least upon the pre-processed EEG signal, wherein the processor is further configured to determine delay information associated with the time the EEG signal is received and the time the level of sedation is determined; and a drug delivery device interface, configured to provide the level of sedation and the delay information to a drug delivery device.

In some embodiments the EEG front end includes an EEG engine and an EMG engine configured to extract EEG information and EMG information from the EEG signal, respectively. In some embodiments, the processor is further configured to time stamp the EEG signal when received from the EEG sensor. In one embodiment, the depth of consciousness monitor also includes an additional sensor front end, such as an SpO2 sensor front end. In some embodiments, the depth of consciousness monitor also includes a data port configured to receive at least one of patient data and drug profile information. The processor may be configured to determine a level of sedation of a medical patient based at least upon the pre-processed EEG signal and the at least one of patient data and drug profile information. In some embodiments, the depth of consciousness monitor also includes the EEG sensor and/or the drug delivery system. In some embodiments, the drug delivery device interface includes a wireless communication device.

In another embodiment, a depth of consciousness monitor is configured to determine the level of sedation of a medical patient. The depth of consciousness monitor includes: an EEG interface configured to receive an EEG signal from an EEG sensor; an EEG front end configured to pre-process the EEG signal; a processor, configured to determine a level of sedation of a medical patient based at least upon the pre-processed EEG signal, and a data port configured to transmit the patient sedation level. The processor can include: two or more computing engines, each configured to compute a possible sedation level according to a different process; and a decision logic module, configured to determine the patient's sedation level based at least upon the possible sedation level computations;

In some embodiments, at least one of the computing engines is configured to implement a motion vector process, a phase coherence process, and/or utilize a brain model to compute one of the possible sedation levels. The EEG front end may include an EEG engine and an EMG engine configured to extract EEG information and EMG informa-

3

tion from the EEG signal, respectively. In some embodiments, the data port comprises a display and/or a wireless communication device.

In yet another embodiment, a method of determining the level of sedation of a medical patient is provided. The method includes: receiving an EEG signal indicative of a medical patient's EEG; receiving treatment data associated with at least one of the medical patient and a drug to be delivered to the medical patient; and determining a level of sedation based at least upon the EEG signal and the treatment data.

In some embodiments, the treatment data includes at least one of a patient age, age classification, sex, weight, body-mass index, a physiological parameters, a temperature, a blood oxygen concentration, an EMG signal, a drug type, a drug class, a mechanism of delivery, and an active ingredient. In some embodiments, determining a level of sedation comprises determining two or more possible levels of sedation with parallel computing engines and wherein said determining the level of sedation of the medical patient is based upon said possible levels of sedation. In some embodiments, determining the level of sedation comprises averaging two or more possible levels of sedation and/or selecting one of the possible levels of sedation as the level of sedation of the medical patient. In some embodiments, determining the possible levels of sedation is performed with motion vector analysis, phase coherence, and or by utilizing a brain model.

For purposes of summarizing the disclosure, certain aspects, advantages and novel features of the disclosure have been described herein. Of course, it is to be understood that not necessarily all such aspects, advantages or features will be embodied in any particular embodiment of the disclosure.

BRIEF DESCRIPTION OF THE DRAWINGS

The following drawings and the associated descriptions are provided to illustrate embodiments of the present disclosure and do not limit the scope of the claims.

FIG. 1 illustrates an embodiment of a depth of consciousness monitoring system under closed-loop control.

FIG. 2 illustrates a block diagram of one embodiment of the depth of consciousness monitor of FIG. 1.

FIG. 3 illustrates one embodiment of the forehead sensor of FIG. 1.

FIG. 4 illustrates one embodiment of an EEG frequency spectrum of the patient before and during sedation using the depth of consciousness monitor of FIG. 2.

FIG. 5 illustrates one embodiment of the processor of the depth of consciousness monitor of FIG. 2.

FIG. 6 illustrates another embodiment of the processor of the depth of consciousness monitor of FIG. 2.

FIG. 7 illustrates yet another embodiment of the processor of the depth of consciousness monitor of FIG. 2.

FIG. 8 illustrates one embodiment of a routine to determine patient sedation information that can be performed by any of the processors of FIGS. 5-7.

FIG. 9 illustrates another embodiment of a routine to determine patient sedation information that can be performed by any of the processors of FIGS. 5-7.

FIG. 10 illustrates another embodiment of a depth of consciousness monitoring system.

FIG. 11 illustrates one embodiment of the depth of consciousness monitoring system of FIG. 10.

FIG. 12 illustrates one embodiment of the depth of consciousness monitoring assembly of FIG. 10.

4

FIG. 13 illustrates the depth of consciousness monitoring assembly of FIG. 12 attached to a sensor assembly.

FIGS. 14-16 illustrate views of the display of a multi-parameter monitor displaying physiological signals received from the depth of consciousness monitor of FIG. 10.

DETAILED DESCRIPTION

The present disclosure generally relates to patient monitoring devices. In order to provide a complete and accurate assessment of the state of a patient's various physiological systems, in an embodiment, a sensor may advantageously monitor one, multiple or combinations of EEG, EMG, cerebral oximetry, temperature, pulse oximetry, respiration, and other physiological parameters. In various embodiments, the sensor includes a disposable portion and reusable portion. For example, the disposable portion may advantageously include components near a measurement site surface (the patient's skin), including, for example, an EEG sensor, an EMG sensor, a temperature sensor, tape, adhesive elements, positioning elements, or the like. In addition, or alternatively, the reusable portion may advantageously include other components, circuitry or electronics, which, in some embodiments include time-of-use restrictions for quality control or the like. The reusable portion, can be used multiple times for a single patient, across different patients, or the like, often depending upon the effectiveness of sterilization procedures. The reusable components may include, for example, cerebral oximetry components, pulse oximetry components and other components to measure other various parameters.

In an embodiment, the disposable portion of the sensor may include an inductance connection or other electrical connection to the reusable portion of the sensor. The physiological signals from all sensors can be transmitted through a common cable to a depth of consciousness monitor. In an embodiment, the depth of consciousness monitor may include an analog to digital converter, various electrical filters, and a microcontroller for processing and controlling the various sensor components.

In an embodiment, a depth of consciousness monitor is configured to communicate with the forehead sensor and one or more host display and patient monitoring stations. In an embodiment, the patient monitoring station may be a pulse oximeter. In an embodiment, the pulse oximeter may perform integrated display, data monitoring and processing of patient parameters including a connection for power and data communication. In an embodiment, some or all communication may be through wired, wireless, or other electrical connections. In an embodiment, the depth of consciousness monitor may advantageously be housed in a portable housing. In such embodiments, the unit may advantageously be physically associated with a monitored patient, such as, for example, attached in an arm band, a patient bed pouch, a hood or hat, a pocket of a shirt, gown, or other clothing, or the like. In other embodiments, the unit may be entirely or partially housed in a cable connector. In an embodiment, the signal processing and condition unit and/or the depth of consciousness monitor could also monitor patient parameters through other sensors including, for example, ECG, SpO₂ from the earlobe, finger, forehead or other locations, blood pressure, respiration through acoustic or other monitoring technologies, or other clinically relevant physiological parameters.

In an embodiment, the depth of consciousness monitor communicates with a sensor, such as a forehead sensor including one or more light sources configured to emit light

at a patient's forehead. In an embodiment, the light source may include one or more emitters or emitter systems, such as emitters or emitter systems may be embedded into a substrate. In various embodiments, the emitters could include light emitting diodes ("LEDs"), lasers, superluminescent LEDs or some other light emitting components. These components could be arranged in any pattern on the substrate and could be either a single light emitting source or several light emitting sources. In an embodiment, the emitting components could emit light that deflects off of reflective surfaces associated with a cap of the substrate. The reflective cover could be any number of shapes or sizes and could be constructed to direct light to specific points or a point on the cap or substrate.

In an embodiment, a multi-faceted splitting mirror could reflect light to an opening in the substrate that would allow the light to escape and be emitted to an emission detector in an embodiment also housed in the light source substrate. The emission detector may advantageously sample the light providing feedback usable to create an optical bench or at least optical bench properties of the light source, including, for example, determinations of intensity, wavelength, or the like. In an embodiment, the light source may include a polarized filter for adjusting the emitter light, in some embodiments before exiting an opening in the emitter or being detected by the emission detector.

In an embodiment, a caregiver could analyze physiological information collected from the various sensors including a patient's temperature, EEG, brain oxygen saturation, stimulus response, electromyography or EMG, respiration using acoustic sensor applied to the through, body oxygen saturation, glucose concentration, or other blood analytes, pulse, hydration, blood pressure, perfusion, or other parameters or combinations of parameters to determine relevant information about the state of a patient's well-being. In another embodiment, a caregiver may advantageously analyze information collected from the various sensors to more completely assess the overall depth of a patient's sedation and obtain an assessment superior to an assessment derived from monitoring a single or a few of the parameters mentioned above.

Reference will now be made to the Figures to discuss embodiments of the present disclosure.

FIG. 1 illustrates one example of a depth of consciousness monitoring system **100**. In certain embodiments, the depth of consciousness monitoring system **100** measures one or more physiological parameters including cerebral electrical activity (e.g., via EEG), cerebral muscular activity (e.g., via EMG), temperature, cerebral oxygenation, including venous and arterial oxygenation, arterial oxygenation at various other points on the body, various other blood analytes, including total hemoglobin, glucose, lipids, stimulus response, electromyography or EMG, respiration, pulse, hydration, blood pressure, perfusion, or other parameters or combination of other physiologically relevant patient characteristics. The information from these physiological parameters can be evaluated using trend analysis, absolute and relative measures of certain parameters, combined or alone to evaluate the total wellness and current state of sedation of a patient.

The depth of consciousness monitoring system **100** includes multiple or a single sensor **120** in communication with a depth of consciousness monitor **140** via a communications link **150**. In the illustrated embodiment, the depth of consciousness monitoring system **100** also includes a drug delivery device **160** that receives a control signal from the depth of consciousness monitor **140** via a control link

170. The drug delivery device **160** provides one or more sedatives (e.g., narcotic, hypnotic, analgesic, opiate, etc.) to a patient **180** via a conduit **190**.

The sensor **120** can include any variety of shapes and sizes, and could be applied to a variety of measurement sites on a patient's skin including any location on the forehead and temples or other location of the head. One example of a sensor **120** configured for placement on a patient's forehead is described below with respect to FIG. 3. The sensor **120** generally includes one or more electrodes and is configured to measure the electrical activity within the patient's head and generate an EEG signal, as discussed in further detail below.

In some embodiments, the sensor's electrodes are designed to be placed at a measurement site covered with a patient's hair. A caregiver or patient may fasten the sensor **120** to the patient's head with a variety of mechanism including adhesive, straps, caps, combinations of the same, or other devices for fastening sensors to a patient's body or skin known in the art.

In some embodiments, the communication link **150** and/or the control link **170** are wired electrical connections (e.g., an electrical cable, etc.). In other embodiments, the communication link **150** and/or the control link **170** utilize wireless communication to provide portability, and greater flexibility in depth of consciousness monitor placement with respect to the drug delivery device **160**. Wireless communications also help accommodate an ambulatory patient, or other patient in transit. For example, in one embodiment, the depth of consciousness monitor **140** may be attached to an arm band or included in an arm band or other device that is wearable by the patient, including in a cap, a hood, a sling or a pocket of a garment. In such an embodiment, the sensor **120** communicates with the arm band depth of consciousness monitor **140** via a wired or a wireless connection.

In an embodiment, the depth of consciousness monitor **140** communicates wirelessly with the drug delivery device **160** over a wireless control link **170**. This allows the depth of consciousness monitor **140** to be transported between various caregiving facilities, each with their own stationary drug delivery devices **160** without unhooking and reinserting hardwired electrical connections. Instead, the depth of consciousness monitor **140** could establish a wireless communication link with a stationary drug delivery device **160** as the depth of consciousness monitor **140** is brought into proximity with the drug delivery device **160**. In an embodiment, the devices could establish the connection automatically and patient data may be automatically sent from the depth of consciousness monitor **140** to the drug delivery device **160**. In other embodiments, caregiver interaction is required to establish a wireless control link **170** between the depth of consciousness monitor **140** and the drug delivery device **160**. Such configurations advantageously facilitate portability and seamless monitoring of a patient while the patient is transported, for example, from an ambulance to a hospital room or from room to room within a hospital.

In an embodiment, the depth of consciousness monitor **140** also communicates with, or incorporates, a pulse oximeter (not shown). The pulse oximeter may be a multi-parameter monitor or other host device capable of monitoring a wide variety of vital signs and blood constituents and other parameters or combinations of parameters such as those monitors commercially available from Masimo Corporation of Irvine, CA, and disclosed herein with reference to U.S. Pat. Nos. 6,584,336, 6,661,161, 6,850,788, and 7,415,297, among others assigned to Masimo Corporation, and U.S. Patent Publication No. 2006/0211924, 2010/

0030040, among others assigned to Masimo Corporation or Masimo Laboratories, Inc. of Irvine CA, all of which are incorporated by reference in their entireties.

The communication link **150** and the control link **170** can include any of a variety of wired or wireless configurations. For example, in some embodiments the links **150**, **170** are implemented according to one or more of an IEEE 801.11x standard (e.g., a/b/g/n, etc.), a BLUETOOTH wireless standard, and a wireless medical information communications standard, etc.

The drug delivery device **160** generally includes at least a drug therapy interface **192**, a drug flow device **194**, and a flow controller **196**. The drug therapy interface **192** receives a drug and provides a flow path to the drug flow device **194**. For example, the drug therapy interface **192** can include a port or receptacle to receive or interface with a drug capsule, intravenous bag, syringe, etc. The drug flow device **194** receives the drug therapy from the drug therapy interface **192** and allows the drug to flow to the patient **180** via the conduit **190**. In some embodiments, the drug flow device **194** includes one or more of a solenoid, a pump, a valve, a peristaltic pump, a variable speed pump, a compression sleeve (e.g., to squeeze an intravenous bag), etc. The action and activation of the drug flow device **194** is controlled by the flow controller **196**. The flow controller **196** includes a microcontroller, a memory, a signal input to receive a control signal from the depth of consciousness monitor **140** via the control link **170** and a signal output to provide control over the functionality of the drug flow device **194**. The signal input can include a wireless radio to facilitate wireless communication over a wireless control link **170**. The signal input allows closed-loop control over the operation of the drug delivery device **160**, as will be described in greater detail below.

In some embodiments, the drug delivery device **160** is manually controlled by a clinician (e.g., an anesthesiologist) and/or includes a manual override to allow the clinician to take control over drug delivery to the patient **180**. Therefore, in some embodiments, the depth of consciousness monitoring system **100** does not include an electronic control link **170** between the depth of consciousness monitor **140** and the drug delivery device. Instead, in such an open-loop configuration, the depth of consciousness monitor **140** displays an indication of the patient's depth of consciousness. The clinician is able to manually adjust drug therapy to the patient in response to the signals displayed by the depth of consciousness monitor **140**.

In some embodiments, the depth of consciousness monitor **140** is configured to generate and/or provide a delay signal (which is a form of delay information) to the drug delivery device **160**. The delay signal may be used by the drug delivery device to control whether the depth of consciousness monitoring system **100** is operating under positive or negative feedback. In some embodiments, the drug delivery device **160** controls or delays the delivery of drugs provided to the patient **180** in response to the delay signal. For example, the drug delivery device **160** may delay drug delivery to make sure that the depth of consciousness monitoring system **100** is operating under negative feedback, and is therefore a stable control system.

The delay signal can be determined by the depth of consciousness monitor **140** in any of a variety of manners. In one embodiment, the depth of consciousness monitor **140** time stamps the data received from the sensor **120** and provides the time stamp information or other related time information to the drug delivery device **160** as the delay signal. For example, in some embodiments, the delay signal

includes the time stamp associated with the data received from the sensor **120** as well as a time stamp associated with the time the control signal data packet is sent to the drug delivery device **160**. In other embodiments, the delay signal includes the difference between the two time stamps. In some embodiments, the drug delivery device **160** is configured to calculate or otherwise determine the appropriate control delay based upon the delay signal. For example, the drug delivery device **160** may time stamp the time the control signal is received from the depth of consciousness monitor **140**. The drug delivery device **160** can determine a control delay based upon the difference between the time the control signal is received from the depth of consciousness monitor **140** and the time the depth of consciousness monitor received the signal from the sensor **120** that was used to generate the associated data packet received by the drug delivery device. The signal propagation delay through the depth of consciousness monitoring system **100** may be used to keep the system's feedback negative to avoid oscillation and to achieve stability.

In an embodiment, a caregiver or the patient may attach the depth of consciousness monitor **140** directly to the patient's arm or other part or clothing of the patient through an armband with straps or some other means known in the art to connect a portable monitoring unit to a patient. In an embodiment, a depth of consciousness monitor **140** may be integrated into a hat or other headgear wearable by the patient or some other structure near the patient. In an embodiment, the depth of consciousness monitor **140** can rest on a table or other surface near the patient.

In some embodiments, a depth of consciousness monitor **140** is integrated with the drug delivery device **160**. Alternatively, the depth of consciousness monitor **140** could be a module that is docked or otherwise attached to the drug delivery device **160**. The depth of consciousness monitor **140** can communicate with and/or be integrated with a variety of other device, such as a pulse oximeter, a respiration monitor, and EKG device, a blood pressure measurement device, a respirator, and/or a multi-parameter monitor.

FIG. 2 illustrates a block diagram of one embodiment of the depth of consciousness monitor **140**, sensors **120**, and drug delivery device **160**. In an embodiment, the depth of consciousness monitor **140** includes a processor **220** which may be a micro-controller or other processor, to control and/or process signals received from the sensors **120**. For example, the processor **220** may coordinate, process or condition, or manipulate the signals received from the sensor **120** to generate electronic data, control signals, and/or delay signals that are subsequently displayed and/or communicated to the drug delivery device **160**. In addition, the processor **220** may receive instructions or data control messages from the drug delivery device **160** or other patient monitoring device to provide the appropriate conditioning and controlling of the various front end components of the sensors **120**. Data transmitted between the depth of consciousness monitor **140**, the drug delivery device **160**, the sensors **120** and any other associated components, devices, or systems in communication with the depth of consciousness monitoring system **100** may be communicated by the devices using one or more interfaces, e.g., electrical wires, wireless communication, optical communication, RFID, LAN networks, or other electronic devices for communicating data known in the art. In one embodiment, a drug delivery device interface can include any one or more of electrical wires, wireless communication, optical communication, RFID, LAN networks, or other electronic devices for communicating data known in the art. In one embodiment,

a multi-parameter physiological monitor interface can include any one or more of electrical wires, wireless communication, optical communication, RFID, LAN networks, or other electronic devices for communicating data known in the art.

The depth of consciousness monitor **140** may also include various front end components to enable the depth of consciousness monitor **140** to process the various signals received by the various sensors **120** that may be communicating with the depth of consciousness monitor **140**. In an embodiment, front end components may translate and transmit instructions and control signals for driving the various sensors. In an embodiment, the front end components may translate, process, or transmit instructions and control signals to the emitting or light producing components of the sensor. The front end components may also receive and transmit data acquired by the detectors of the sensors to the microcontroller **220** or other processor **220**. The front end components can include one or more of an analog-to-digital converter, a preamplifier, an amplifier, a filter, a decimation filter, a demodulator, etc.

These front end components could include front end components for a variety of sensors **120** including for sensors that detect blood oxygenation, EEG, EMG, ECG, temperature, acoustic respiration monitoring ("ARM") sensors, such as those available from Masimo Corporation of Irvine, CA, acoustic throat respiratory sensor, and brain oxygenation. In an embodiment, a caregiver could advantageously utilize a device with the ability to monitor the plurality of above mentioned parameters to more accurately determine a depth of a patient's sedation. However, in some embodiments, the depth of consciousness monitor **140** only includes EEG and EMG front end components. In an embodiment, a front end component that would be associated with a sensor **120** that detects brain oxygenation may have a sub component dedicated to driving emitters **230** associated with a light source of the brain oxygenation sensor and a sub-component associated with the detector **230** or detectors **230** of the brain oxygenation sensor **300** for receiving and transmitting the detected signals that pass through various body tissues. In other embodiments, the light drivers and detector front end are omitted.

In an embodiment, one of the various sensors associated with the front end components of the brain oximetry unit could be, for example, a blood oxygenation sensor **310** which may be placed at various measurement sites on a patient's skin, including the earlobe, finger, forehead or other places known in the art suitable for detecting blood oxygenation. Many suitable pulse oximeter sensors **310** are known in the art such as those blood oxygenation sensors **310** commercially available from Masimo Corporation of Irvine, CA, including but not limited to those described in U.S. Pat. Nos. 5,638,818, 6,285,896, 6,377,829, 6,580,086, 6,985,764, and 7,341,559, which are expressly incorporated by reference in their entireties.

In an embodiment, a temperature sensor **320** communicates with an associated front end component of the depth of consciousness monitor **140**. The temperature sensor **320** detects the temperature of the skin, the temperature inside the ear, the temperature under the tongue, or any other temperature measurement method known in the art. In an embodiment, the temperature sensor **320** could be any suitable thermistor, or any other temperature sensor **320** known in the art capable of detecting a surface temperature of a patient's skin. Additional temperature sensor may advantageously provide feedback to the depth of conscious-

ness monitor **140** regarding the performance or temperature of one, combinations of, or all of the emitters **230**.

An EEG sensor **330** may also be associated with the front end components of the depth of consciousness monitor **140**. In an embodiment, the EEG sensor **330** may be any of a variety of EEG sensors **330** known in the art. An EEG sensor **330** could be applied to a patient at any of a multitude of locations and measurement sites on the skin of the head of a patient. In an embodiment, the EEG sensor **330** may include electrode leads that may be placed on a measurement site in contact with the skin of the patient. In an embodiment, the EEG **330** may monitor the electrical activity of a patient's brain through any number of electrodes, electrode leads, and channels or other systems known in the art. One such EEG sensor **330** is illustrated in FIG. **3** and described in greater detail below.

In an embodiment, the EEG sensor **330** may monitor and collect data from a patient's brain using 4 channels and 6 electrodes. In another embodiment, the EEG **330** may use 3 channels and 5 electrodes. In another embodiment, any variety or combination of sensors may be used that are suitable for obtaining an EEG signal, such as those described in U.S. Pat. Nos. 60/164,444, 6,654,626, 6,128,521, which are incorporated by reference in their entireties.

A brain oxygenation sensor **300** may also be associated with the front end components of the depth of consciousness monitor **140**. In an embodiment, the brain oxygenation sensor **300** includes a light source **230**, and a detector **260**. The light source **230** of the brain oxygenation sensor **300** includes emitter(s) that would emit light, sonic or other radiation into the forehead at one, two or other plurality of measurement sites located on the skin of the patient at a plurality of predetermined wavelengths. In an embodiment, the brain oxygenation sensor **300** would include a detector **260** with photodiodes or other radiation detection devices to detect the radiation emitting from the patient at a one or two or a plurality of measurement sites on the skin of the head of a patient. Many suitable brain oxygenation sensors **300** and cerebral oximeters are known in the art including those disclosed in U.S. Pat. Nos. 7,072,701, 7,047,054, which are expressly incorporated by reference in their entireties.

In an embodiment, the light source **230** of the brain oxygenation sensor **300** may include an emission detector **260**. In an embodiment, the emission detector **260** detects the light emitted from the light source **230** before passing through or contacting the measurement site of the patient. In an embodiment, an output from the emission detector **230** would be communicated to the micro-controller **220** of the depth of consciousness monitor **140** in order to calculate an approximate output intensity of the light emitted by the emitter(s) **230**. The micro-controller **220** or other processor **220** could calculate the output intensity based on the output of the emission detector **260** by comparing the data to calibration data. In an embodiment, the calibration data could include measurement of intensity of light emitted from the emitter(s) **230** and corresponding measurements of output from the emission detector **260**. This data could then be correlated to real time output from the emission detector **260** while the oxygenation sensor **230** is in use to determine an actual or approximate intensity of light or radiation being emitted by the emitter(s) **230** utilizing a calibration curve or other suitable calculation or processing method. In an embodiment, the calibration data may be stored in an EPROM or other memory module in the depth of consciousness monitor **140** or other patient processing module or device associated with the patient monitoring system **100**.

11

In an embodiment, the detector **260** detects light or other radiation emitted from the light source **230** after, in an embodiment, some of the light has entered the measurement site on the patient and has been attenuated by a patient's tissue. In an embodiment, the detector **260** could be any number of detectors known in the art for detecting light or other radiation including photodiodes or other types of light or radiation detectors. In one embodiment, the detector **260** may convert detected light or other radiation into a signal, for example, an electrical output signal, which may represent the intensity or other attributes of the radiation. In an embodiment, the signal from the detector **260** may be sent to a brain oxygenation detector **260** front end located in the depth of consciousness monitor **140** for processing, conditioning or transmitting to a pulse oximeter (not shown) or other patient monitoring processor. In one embodiment, the signal may be converted into a digital format by an analog to digital converted located in the depth of consciousness monitor **140**. In an embodiment, the data from the detector **260** of the brain oxygenation sensor **300** may be processed to determine the cerebral oxygenation of a patient's brain tissue. In an embodiment, the processing of the data may include determining the changes of intensity between various wavelengths of emitted and detected light of the cerebral oxygenation sensor **300**.

In an embodiment, a cerebral oximeter or multi-parameter monitor (not shown) acquires data from the depth of consciousness monitor **140** or sensor **120** derived from physiologically relevant parameters. In an embodiment, the pulse oximeter could provide visual quantitative or qualitative assessments of the patient's well-being based on one or more of the various parameters or physiological attributes measured.

In an embodiment, a caregiver may utilize various physiological parameters to make a quantitative assessment of the patient's depth of sedation as indicated by an index based on for example, a patient's temperature, electroencephalogram or EEG, brain oxygen saturation, stimulus response, electromyography or EMG, respiration based on acoustic through sensors, body oxygen saturation or other blood analytes, pulse, hydration, blood pressure, perfusion, or other parameters or combinations of parameters. In another embodiment, various aspects of sedation could be assessed quantitatively or qualitatively based on a visual representation of the patient's sedation in the aspects including hypnosis, responsiveness, muscle relaxation or other clinically relevant facets of depth of anesthesia.

In an embodiment, the functionality of the depth of consciousness monitor **140** could be optionally controlled by the drug delivery device **160**. In an embodiment, the data and qualitative and quantitative assessments of a patient's wellness being could be displayed on one or more of the depth of consciousness monitor **140**, the drug delivery device **160**, or any other device or system in communication with the depth of consciousness monitoring system **100** (e.g., a pulse oximeter, physiological patient monitor, nurse station, etc.). Also, audible alarms and other indicators could be displayed on either or both the depth of consciousness monitor **140** and drug delivery device in response to various threshold breaches based on the assessment of the patient's wellness and depth of consciousness as determined from the various monitored parameters.

FIG. 3 illustrates one embodiments of a sensor **120** in the form of an EEG sensor **410**, which is configured for placement on a patient's forehead to generate an EEG signal. Disposable and reusable portions of the sensor **410** may be connected and overlaid on top of one another. The EEG

12

sensor **410** includes six EEG electrodes **440** with two reference electrodes (along the central axis of the EEG sensor **410**) and four active channel electrodes (two on each side of the EEG sensor's central axis). In some embodiments, light source(s) and light detector(s) (not shown) may be incorporated into the EEG sensor **410**, as well. All or some of the above mentioned sensor components including the EEG electrodes **440**, leads from the electrodes **440**, and blood oxygen detecting light emitters and detectors (when provided) may communicate with one or more chips **420** that enables transmission of acquired signals and drive signals. In some embodiments a single chip **420** is provided. In other embodiments, each component communicates with its own individual chip through wires, or printed circuits, or other suitable electrical connections.

The EEG electrodes **440** may be any suitable electrodes for detecting the electro-potentials on the surface of the skin of a patient's head. In one embodiment, EEG electrodes **440** include a metal or other suitable conductor and utilize leads contacting the surface of the skin. In another embodiment, the electrodes **440** are gelled electrodes that make contact through the skin via gel and have metal leads that come into contact with the gel. In still yet another embodiment, the EEG electrodes **440** may be glued to the forehead with any suitable patient dermal adhesive for connecting the EEG electrodes **440** and may have electrical conductivity. In an embodiment, potentials from the EEG electrodes **440** are transmitted to the depth of consciousness monitor **140** for further conditioning, transmitting or processing.

The sensor **410** may also include one or more temperature sensors (not shown). The temperature sensor may be any suitable sensor that can detect the temperature of the surface of the skin or other patient temperatures. In an embodiment, the temperature sensor may include a thermistor attached to a reusable portion of the sensor **410**.

In an embodiment, the sensor **410** includes an interface **450** to couple the sensor **410** to the depth of consciousness monitor **140**. The interface **450** may be any suitable electrical or data connection or communication port or device including, for example, a pin connector and receiver. Various other communication or electrical connections known in the art may be utilized. In an embodiment, the interface **450** may include an inductance connection utilizing transformers to couple a data and electrical connection across an insulator. In another embodiment, the interface **450** provides a data or electronic coupling between a reusable portion and a disposable portion of the sensor **410**.

In some embodiments, the sensor **410** includes a disposable portion (not shown) removably attached to a reusable portion (not shown). In an embodiment, the disposable portion attaches to a measurement site of a patient's head and provides a base to which the reusable portion may be docked, mated or connected. The disposable portion houses the components of the sensor **410** that may be less expensive than at least some of the components contained in the reusable portion, and therefore may be disposed after a single or multiple uses, either on the same patient or different patients. The disposable portion of the sensor **410** includes a tape substrate that provides a base or substrate to which at least some of the components of the disposable portion may adhere or be integrated. In an embodiment, the tape can be constructed from any suitable disposable material that will effectively hold the components includes in the disposable portion to a patient's forehead or other measurement site. In an embodiment, the tape includes a suitable dermal adhesive on a patient side of the disposable portion for temporary adhesion of the sensor to a patient's skin.

13

In an embodiment, the sensor **410** may include an adhesive tape **430** that supports the EEG electrodes **440**. In one embodiment, the EEG electrodes **440** may be fastened to the tape **430**. In an embodiment, the EEG electrodes **440** could be embedded in the tape **430** by any known adhesive in the sensor arts or any other suitable means for connecting the EEG electrodes **440** that would allow the EEG electrode **440** leads to be exposed on a patient side of tape **430** in an appropriate position to come in close proximity to a measurement site of a patient's skin. In an embodiment, EEG electrodes **440** may be gelled so that the gel contacts the electrodes and a measurement site of a patient's skin to provide an electrical path between the measurement site of the patient's skin and the EEG electrodes **440**. In an embodiment, the leads of the EEG electrodes **440** are connected to a chip **420** by wires or other suitable electrical connections, such as a printed circuit, flex circuit, etc.

The sensor **410** may also include a temperature sensor (not shown). In an embodiment, the temperature sensor includes a thermistor with the thermistor leads exposed on a patient contacting side of the tape **430**, in order to facilitate the contacting of the leads of temperature sensor to a measurement site of a patient's skin. In an embodiment, the temperature sensor is connected to single chip through wires or other suitable electrical connections such as a flexible printed circuit. In an embodiment, the temperature sensor may be located anywhere on the tape **430**, the disposable portion or the reusable portion of the sensor **410** (if the sensor is provided with disposable and reusable portions). In an embodiment, the leads for the temperature sensor may be near the center of tape **430** or anywhere on the periphery of tape **430**.

In some embodiments, the sensor **410** includes a pulse oximeter sensor (not shown). The pulse oximeter sensor can include an ear pulse oximeter sensor that emits and detects radiation to determine the oxygenation of the blood traveling through the arteries of the ear. Many suitable ear pulse oximeter sensors are known in the art such as those sensors commercially available from Masimo Corporation and disclosed herein with reference to U.S. Pat. No. 7,341,599, which is expressly incorporated by reference in its entirety. In another embodiment, the pulse oximeter sensor may be a forehead pulse oximeter sensor or any other suitable pulse oximeter known in the art or disclosed herein. The pulse oximeter sensor may be connected to the sensor **410** through electrical wires, wirelessly or other suitable electrical or data connection. Data collected from the pulse oximeter sensor may be transmitted to the depth of consciousness monitor **140**, pulse oximeter, or both for conditioning and further processing.

In some embodiments, signal processing and conditioning circuitry of depth of consciousness monitor configured to monitor the EEG signals of a patient and providing feedback on the depth of sedation or awareness of a patient undergoing anesthesia, may be partially or entirely incorporated into the sensor **410**. Sedation brain function monitors, including those similar to the SEDLINE sedation monitor commercially available from Masimo Corporation of Irvine, CA, as well as those described in U.S. Pat. Nos. 6,128,521, 6,301,493, 6,317,627, 6,430,437, all of which are expressly incorporated by reference in their entireties. For example, the sensor's connector or interface **450** may house the circuit board, with six channels for six detectors and a processor configured to determine depth of consciousness.

Integration of all or the majority of the associated circuitry and processing components of several different patient monitoring sensors in a single sensor advantageously

14

provides a caregiver a simple device that can be attached to the patient's forehead and/or other areas on the patient, to provide minimal discomfort to the patient and minimal amount of wires and connections to cause electrical interference with instruments in the hospital environment. Additionally, the caregiver will spend less time attaching various sensors to a patient where each would otherwise require its own associated monitoring station. Furthermore, integration of sensor processing components allows some of the processing components to have shared functionality and therefore saves considerably on manufacturing costs. For example, memory chips, processors, or other electrical components may be shared by the various sensors.

EEG Signal Processing

Referring again to FIG. 2, the depth of consciousness monitor's processor **220** is configured to receive at least an EEG signal from an EEG sensor **330** using an interface, such as an EEG interface **332** and process the EEG signal to determine the patient's depth of consciousness. In some embodiments, the processor **220** determines an index value between 0 and 100 to indicate depth of consciousness. The depth of consciousness monitor **140** may include a display, such as a monitor, LED, speaker, etc., to indicate the patient's depth of consciousness, e.g., the index value.

In some embodiments, the processor **220** determines the frequency content of the EEG signal prior to administration of any sedatives as well as during sedation. FIG. 4 illustrates one embodiment of a graph **500** showing the patient's EEG's frequency content or frequency spectrum prior to sedation as curve **510** and during sedation as curve **530**. Shifting of the curve **510** amplitude at frequencies below 10 Hz, a drop in curve slope at frequencies above 10 Hz, and the formation or increase in the frequency curve **510** to form a local maximum (e.g., local maximum **540**) at 10 Hz each indicates that the patient has entered a sedated state.

Indeed, in one embodiment, the processor **220** determines whether the patient is adequately sedated by monitoring for the presence of a local maximum **540** in the frequency curve **530** above a predetermined threshold value, at 10 Hz. However, the shape of the frequency curve **530** can vary based upon several factors, such as any one or more of the patient's age, age classification (e.g., pediatric, adult, geriatric, etc.), sex, weight, body-mass index, genetic factors, etc. The shape of the frequency curve **530** can also vary based upon one or more physiological parameters associated with the patient, such as the patient's temperature, blood oxygen concentration, EMG signal, etc. Furthermore, the shape of the frequency curve **530** can also vary based upon the particular drug administered to sedate the patient. For example, the drug type, drug class (e.g., hypnotic, analgesic, opiate, etc.), mechanism or method of delivery (inhalant, intravenous, ingestible, etc.) and/or particular active ingredient (e.g., Propofol (TIVA), Sevoflurane, nitrous oxide, morphine, etc.) can each affect the shape of the frequency curve **530**. Variations in the frequency curve **530** make it more difficult for the depth of consciousness monitor **140** to accurately determine whether the patient is adequately sedated.

Therefore, to improve accuracy, in one embodiment the depth of consciousness monitor's processor **220** analyzes the frequency curve **530** by considering one or more curve profiles associated with the patient and/or the drug administered. For example, in one embodiment, the processor **220** obtains physiological information regarding the patient from sensors **120** attached to the depth of consciousness monitor **140**. In other embodiments, the processor **220** obtains physiological information regarding the patient via a data port.

For example, the data port can receive temperature, blood oxygen saturation, respiration rate, and/or other physiological parameter information from an separate monitor. In addition, the depth of consciousness monitor **140** can receive additional information regarding the patient and the drug via the data port, as well.

For example, in some embodiments, the data port includes a wireless radio, a network adapter, a cable, an Ethernet adapter, a modem, a cellular telephone, etc., to receive patient and/or drug information. The patient and/or drug information is provided to the processor **220** to accurately interpret the frequency curve **530** derived from the EEG sensor **330** signal. In one embodiment, the data port includes a keyboard or other data entry device that allows the clinician to manually enter data relating a patient or drug parameters, such as those examples described above. Indeed, the processor **220** can include one or more EEG processing engines that are configured based upon the patient and/or drug data received by the depth of consciousness monitor **140**, as discussed in greater detail below.

In some embodiments, the patient's frequency response graph **500** is processed as four distinct, non-overlapping frequency bands **550**, **552**, **554**, **556**. For example, the first frequency band, sometimes referred to as the delta band, is the portion of the graph **500** between 0 and 4 or about 4 Hz. The second frequency band, sometimes referred to as the theta band, is the portion of the graph **500** between 4 or about 4 Hz and 7 or about 7 Hz. The third frequency band, sometimes referred to as the alpha band, is the portion of the graph **500** between 7 or about 7 Hz and 12 or about 12 Hz; and the fourth frequency band, sometimes referred to as the beta band, is the portion of the graph **500** greater than 12 or about 12 Hz.

In some embodiments, the depth of consciousness monitor **140** determines whether there is a peak **540** greater than a predetermined threshold in the frequency curve **530** anywhere within the alpha band **554**. If so, the monitor **140** may determine that the patient is adequately sedated. However, in some cases, the peak **540** can shift and appear outside of the alpha band **554**. For example, a sedated patient that is experiencing hypothermia may not manifest a peak in the alpha band; instead, the peak may shift to the theta or beta bands.

Therefore, in one embodiment, the depth of consciousness monitor **140** does not limit its search for a peak **540** to a particular frequency value (e.g., 10 Hz) or a particular frequency band (e.g., alpha band **554**). Instead, in such an embodiment, the depth of consciousness monitor **140** scans across all frequencies (or a larger subset of frequencies than just those within the alpha band) to search for a peak **540** (e.g., across two or more frequency bands). A detected peak may be used to determine alone (or in combination with other patient and/or drug data) whether the patient is adequately sedated.

The peak **540** can be defined in any of a variety of clinically-relevant manners. For example, the peak **540** can be defined based upon the slope of the curve segment on one or both sides of the peak **540**, the relative magnitude of the peak compared to the curve values at predetermined locations or offsets on either side of the peak **540**, the relative magnitude of the peak compared to the frequency curve **510** of the patient obtained prior to sedation, etc.

In one embodiment, the processor **220** processes the patient's frequency spectra curve **510**, **530** as deformable curves by utilizing motion vector processing. For example, the processor **220** compares each point (or a predetermined number of points) in the pre-sedation curve **510** to points

within the sedation frequency curve **530** to match points having the greatest similarity (e.g., relative position with respect to its neighbors, pattern matching, sum of absolute differences, any pattern matching technique, etc.). The processor **220** determines one or more motion vectors **560** to describe the motion of the points from one curve **510** to the next **530**. Each motion vector **560** includes both direction and amplitude (e.g., distance traveled) information. Although the graph **500** includes curve **510**, **530** illustrated in the frequency domain (the x-axis represents frequency), the motion vectors **560** include time domain information. For example, the processor **220** can look at multiple frames of data (e.g., multiple graphs **500**) and employ pattern matching techniques (e.g., sum of absolute differences) to determine which points in the graphs **500** and their curves **510**, **530** to use to define the respective motion vectors **560**. In some embodiments, the motion vectors **560** are determined at 0.5, 1, 2, or 2.5 Hz intervals.

One or more motion vector **560** profiles may be constructed based upon particular drug and patient data. For example, each drug used for sedation may be characterized by a unique set of motion vectors. When a patient is treated with a particular drug, and the patient's motion vectors match those of the drug (e.g., the drug profile), the processor **220** can determine that the patient is adequately sedated. Such profiles may be determined for any one or more of the patient's age, age classification (e.g., pediatric, adult, geriatric, etc.), sex, weight, body-mass index, genetic factors, etc., physiological parameters associated with the patient, such as the patient's temperature, blood oxygen concentration, EMG signal, etc., the particular drug administered to sedate the patient, the drug type, drug class (e.g., hypnotic, analgesic, opiate, etc.), mechanism or method of delivery (inhalant, intravenous, ingestible, etc.) and/or particular active ingredient (e.g., Propofol (TIVA), Sevoflurane, nitrous oxide, morphine, etc.). Such profiles may be stored within the depth of consciousness monitor's memory, or they may be retrieved from one or more data repositories stored at one or more remote locations (e.g., over a computer network, over the Internet, from a server, from the cloud, etc.).

In another embodiment, the EEG front end circuitry is configured not to eliminate or filter out low frequencies. The EEG front end circuitry instead allows the processor **220** to determine slow waves (e.g., time-domain signals at or below 1, 0.5, and/or 0.2 Hz). The processor **220** can employ one or more phase coherence methods to detect phase coherence between one or more slow waves and one or more patient signals falling within one of the frequency bands **550**, **552**, **554**, **556**. For example, in some embodiments, phase coherence between a slow wave and a signal from the theta band **552** indicates that the patient is awake. Once the slow wave and signal from the theta band **552** are out of phase, the patient is sedated. In other embodiments, phase coherence analysis is performed to compare phase coherence between a selected slow wave and a different frequency band's signals (e.g., the delta band **550**, the alpha band **554**, and/or the beta band **556**). In some embodiments, the processor **220** performs phase coherence analysis between a selected slow wave and multiple signals between 4 and 50 Hz, e.g., every 0.2, 0.5, 1, or 2 Hz. In other embodiments, phase coherence is determined along the entire frequency spectrum.

In yet another embodiment, the processor **220** generates and/or utilizes a mathematical or electrical model of brain activity to determine whether the patient is adequately sedated. The model can be used to predict what the EEG of a sedated patient should look like based upon a particular

drug, drug delivery mechanism, concentration (or any other drug parameter, including those discussed above). Actual EEG signals may be compared to the signal predicted by the model to determine whether the patient is adequately sedated. The model can be constructed of various combinations of electrical components (e.g., resistors, capacitors, amplifiers, etc.) or computing elements.

In one embodiment, brain modeling occurs by storing EEG signals from sedated patients in a memory location and categorized the EEG signals based upon any of a variety of drug and patient data information. For example, sedated EEG signals may be categorized based upon the particular drug, dosage, concentration, delivery method, etc. used to treat the patient. A brain response model is constructed by combining the various data into a single model.

In some embodiments, the processor 220 includes a pre-processor 602, a compute engine 604, and a post processor 606, as illustrated in FIG. 5. The patient's EEG signal is received by the pre-processor 602. The pre-processor 602 performs front end processing, such as one or more of filtering, amplification, A/D sampling, decimation, demodulation, etc. of the EEG signal. In some embodiments, the pre-processor 602 includes the EEG front end functionality discussed above with respect to FIG. 2. The compute engine 604 determines the level of patient sedation and/or depth of consciousness utilizing, for example, any of the techniques described herein. In one embodiment, the compute engine 604 determines an index value representative of the patient's sedation level. The post-processor 606 provides an indication of the patient's sedation level as well as other relevant information (e.g., system delay, as discussed above, other physiological parameter information, pass-through signals, etc.) for display to the clinician and/or transmission to a drug delivery device or other physiological monitor or information display station. In some embodiments, the post-processor 606 stores patient sedation, EEG signals, patient data and drug information in a memory location.

Another embodiment of a processor 220 is illustrated in FIG. 6. The processor 220 includes a pre-processor 602, multiple compute engines 604a, 604b, . . . 604n, and decision logic 608. Each compute engine 604a, 604b, . . . 604n determines patient sedation information utilizing different processing approaches. For example, one compute engine 604 may determine patient sedation information utilizing motion vector analysis (e.g., as discussed above), one compute engine 604 may determine patient sedation information utilizing frequency coherence analysis (e.g., as discussed above), etc. Furthermore, each compute engine 604 can be drug or patient information specific. For example, the compute engine 604 may utilize historical information (either of the patient himself or from a model, etc.) to determine patient sedation. Each compute engine 604 could therefore correspond to a particular patient's age, age classification (e.g., pediatric, adult, geriatric, etc.), sex, weight, body-mass index, genetic factors, etc., physiological parameters, such as temperature, blood oxygen concentration, EMG signal, etc., the particular drug administered to sedate the patient, such as the drug type, drug class (e.g., hypnotic, analgesic, opiate, etc.), mechanism or method of delivery (inhalant, intravenous, ingestible, etc.) and/or particular active ingredient (e.g., Propofol (TIVA), Sevoflurane, nitrous oxide, morphine, etc.). The compute engines 604 may operate simultaneously to parallel process EEG information.

A decision logic module 608 receives the outputs of each compute engine 604 and applies logic to determine the best estimate of the patient's sedation level. For example, in

some embodiments, the decision logic module 608 averages or weighted averages the outputs of the compute engines 604. In other embodiments, the decision logic module 608 selects one or more compute engine outputs based upon known information about the patient and/or drug(s) used for sedation. The decision logic output 610 can indicate one or more parameters relevant to patient sedation. For example, in some embodiments, the decision logic output 610 includes suppression bar, EMG estimation, patient sedation index, drug type and patient age estimates. If any one or more decision logic outputs do not match actual drug or patient profile information, an alarm can activate. In other embodiments, the clinician manually compares the decision logic outputs to actual drug and patient profile information to confirm the accuracy of the depth of consciousness monitor 140.

Another embodiment of a depth of consciousness monitor's processor 220 is illustrated in FIG. 7. The processor 602 includes a pre-processor 602, compute engines 604 and decision logic 608, as discussed above with respect to FIG. 6. In addition, the processor 220 includes an EEG engine 620 and an EMG engine 630. The EEG and EMG engines receive a pre-processed EEG signal from the pre-processor 602. The pre-processed EEG signal will generally contain both EEG and EMG content. For example, EEG content describes the electrical activity within the patient's brain and the EMG content describes the electrical activity associated with the muscular contractions in the patient's forehead, near the EEG sensor. The EEG and EMG engines 620, 630 separate the EEG and EMG content from the pre-processed EEG signal. The outputs of the EEG and EMG engines 620, 630 communicate with the inputs of one or more compute engines 604. The EEG signal from the EEG engine provides an indication of the patient's hypnotic state, while the EMG engine provides an indication of the patient's analgesic response, or pain state. Separating the two provides more information about the patient's state, and allows improved depth of consciousness processing. When EMG content is included in the EEG signal, the frequency response curve is flatter at higher frequencies (e.g., at frequencies in the beta band).

FIG. 8 illustrates one embodiment of a process 700 to determine a patient's sedation level that can be implemented by any of the processors described above. The process 700 begins at block 702. At block 702, the process 700 receives an EEG signal from a patient. At block 704, the process 700 receives treatment data. The treatment data may include one or more of patient data and drug profile information. The patient data can include any of the patient data or drug profile information described above. At block 706, the process 700 selects a computing engine based upon one or more treatment data. At block 708, the process 700 computes patient sedation information using EEG information and the selected computing engine. The patient sedation information can include one or more of a patient sedation level or index, an EMG level, a prediction of the drug used to sedate the patient, a prediction of the patient's age, etc. The process 700 ends at block 708.

FIG. 9 illustrates another embodiment of a process 800 to determine a patient's sedation level that can be implemented by any of the processors described above. The process 800 begins at block 802. At block 802, the process 800 receives an EEG signal from a patient. At block 804, the process 800 receives treatment data. The treatment data may include one or more of patient data and drug profile information. The patient data can include any of the patient data or drug profile information described above. At block 806, the

process **800** computes patient sedation information with parallel computing engines using the EEG information. The patient sedation information can include one or more of a patient sedation level or index, an EMG level, a prediction of the drug used to sedate the patient, a prediction of the patient's age, etc. At block **808**, the process **800** determines patient sedation information by selecting the output of one of the parallel computing engines, or by combining one or more computing engine outputs (e.g., averaging, weighted averaging, etc.). The process **800** ends at block **808**.

FIG. **10** illustrates one embodiment of a depth of consciousness monitoring system **1000**. The system **1000** includes a depth of consciousness monitor assembly **1002**, a multi-parameter monitor **1012**, and a sensor **1014**. The monitor assembly **1002** includes a depth of consciousness processor **1003**, which can include any of the processors described above. In some embodiments, the processor **1003** is configured to perform one or more of the methods described above.

The assembly **1002** may be provided in the form of a cable. For example, the assembly **1002** may include one or more cables **1004** (or cable portions) that terminate in connectors **1005**, **1008** located at the cable ends **1006**, **1010**. In the illustrated embodiment of FIG. **10**, the assembly **1002** includes two cables **1004**. The first cable **1004** has two ends and is coupled to the processor **1003** at one end and terminates at a connector **1005** at the other end **1006**. In one embodiment, the connector **1005** (which is one embodiment of an interface, such as a multi-parameter monitor interface) is configured facilitate communication between the processor **1003** and a medical device, such as a physiological monitor, display instrument, and/or a multi-parameter monitor **1012**, etc. In some embodiments, the connector **1005** receives power from a multi-parameter monitor **1012** to power the depth of consciousness processor **1003**. In some embodiments, the processor **1003** is configured to consume less than about 250 mW, 500 mW or 1 W at about 4.75 V, 5 V or 5.25 V.

Physiological signals generated by the depth of consciousness processor **1003** are communicated to the multi-parameter monitor **1012** via the connector **1005**. The multi-parameter monitor **1012** is configured to display one or more of the signals generated by the depth of consciousness processor **1003**. In one embodiment, the cable **1004** that terminates at the multi-parameter monitor **1012** connector **1005** is configured to provide and/or receive power, ground, data+ and data- signals. For example, in one embodiment, the cable **1004** includes four conductors, one each for power, ground, data+ and data-.

An adapter or coupler (not shown) may be provided to facilitate coupling of the connector **1005** to the multi-parameter monitor **1012**. For example, an adapter having first and second ends can be configured to have different shapes and pin configurations to allow communication and physical coupling of the connector **1005** to the multi-parameter monitor **1012**. In some embodiment, the adapter (not shown) also includes conditioning circuitry to facilitate communication and/or power transmission between the multi-parameter monitor **1012** and the processor **1003**. For example, the adapter may provide voltage regulation, electrical isolation, signal multiplexing, etc.

The second cable **1004** has two ends and is coupled to the processor **1003** at one end and terminates at a connector **1008** at the other end **1010**. In one embodiment, the connector **1008** is configured to facilitate communication with a physiological sensor **1014**, such as an EEG sensor, and/or any other sensor described above via an interface **1015** (e.g.,

interface **450** of FIG. **3**). In one embodiment, power from the multi-parameter monitor **1012** is directly or indirectly (e.g., after further filtering, conditioning, pulsing, etc. by the processor **1003**) communicated to the sensor **1014**. Signals (e.g., e.g., measured patient signals) from the sensor **1014** are communicated to the processor **1003** via the interface **1015**, which can be coupled to the connector **1008**.

FIG. **11** illustrates another embodiment of a depth of consciousness monitoring assembly **1002** coupled to a multi-parameter monitor (sometimes referred to as a multi-parameter instrument) **1012**. The multi-parameter monitor **1012** is configured to receive and display a plurality of physiological parameters received from a patient monitoring device, such as, but not limited to, the depth of consciousness monitoring assembly **1002**. The multi-parameter monitor **1012** includes a display **1020**. The display **1020** is configured to display a plurality of physiological signals **1022** related to a medical patient. In some embodiments, the display **1020** can be configured to display only selected or groups of physiological signals **1022**. In some embodiments, the monitor **1012** can be configured to display a particular view or mode on the display **1020**. The view or mode can include one or more pre-selected groupings of physiological signals to display. Examples of different views that may be provided via the display **1020** are discussed below with respect to FIGS. **14-16**. Other views, in addition to or instead of those illustrated in FIGS. **14-16** may be displayed on the multi-parameter monitor **1012** display **1020**, as well.

In some embodiments, the multi-parameter monitor **1012** also includes a removable module **1024**. The removable module **1024** can include a physiological monitor configured to determine one or more physiological parameters associated with the medical patient. For example, in some embodiments, the removable module **1024** includes a respiration rate monitor, a blood oxygen saturation monitor, a blood gas monitor, a carbon monoxide monitor, an ECG monitor, an EKG monitor, a blood pressure monitor, a temperature monitor, a heart rate monitor, etc., or a combination of any one or more of the foregoing.

In the illustrated embodiment of FIG. **11**, the depth of consciousness monitor assembly **1002** only includes one cable **1004**. A first end of the cable **1004** terminates at a connector (not shown) that is attached to the multi-parameter monitor **1012**. The second end of the cable **1003** includes the depth of consciousness processor **1003** and connector **1008**, which are integrated within a single housing assembly. The connector end of a sensor **1014** is shown attached to the depth of consciousness monitor assembly's **1002** cable's **1003** second end.

FIG. **12** illustrates another embodiment of a depth of consciousness monitor assembly **1002**. The processor **1003** is positioned between the ends **1006**, **1010** of the assembly **1002**. The length of the cable **1004** attached to the connector **1008** configured to attach to a sensor (not shown) may be shorter than the length of the cable **1004** attached to the connector **1005** configured to attach to the multi-parameter monitor (not shown). The shorter sensor cable **1004** length can provide additional comfort and less pulling on the sensor when attached to the patient. FIG. **13** illustrates the depth of consciousness monitor assembly **1002** coupled to a sensor **1014**. The sensor **1014** can include any of the EEG sensors described above.

FIGS. **14-16** illustrate views of various parameters **1022** that may be displayed on the multi-parameter monitor **1012** display **1020**. The embodiment of FIG. **14** illustrates an EEG view of a multi-parameter monitor **1012**. The multi-parameter monitor **1012** view includes a numeric value indicator

(e.g., EEG data, insufficient EEG data, patent state index (PSI) value), or any other value described herein, etc.), a bar-graph indicator, menu indicators, date and time indicators, message indicators, physiological waveform indicators, and system status indicators. The physiological waveform indicators can display each of the waveforms received from each electrode (e.g., R2, R1, L1) of an sensor **1014**, such as an EEG sensor.

FIG. **15** illustrates a trend view of a multi-parameter monitor **1012**. The multi-parameter monitor **1012** view includes a primary indicator or display and a secondary indicator or display. The primary indicator displays the trend of one or more physiological parameters (e.g., PSI, etc.) over time. One or more secondary indicators can display additional physiological parameters of the medical patient, including but not limited to, EMG, and SR. In one embodiment, the secondary indicators display information in the same format (e.g., waveform, solid waveform, bargraph, etc.) as the primary (e.g., trend plot) indicator, but at a smaller size. In other embodiments, the secondary indicators display information in a different format than the primary (e.g., trend plot, etc.) indicator. FIG. **16** illustrates a density spectral array view of a multi-parameter monitor **1012**. The multi-parameter monitor **1012** view includes a spectral density indicator

Each of the displayed physiological parameters can be determined by the depth of consciousness processor **1003**. In addition, the multi-parameter monitor **1012** can be configured to display any one or more of the parameters discussed above, as well as other parameters, such as signals from the removable module **1024**, when provided.

All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

Depending on the embodiment, certain acts, events, or functions of any of the processes or algorithms described herein can be performed in a different sequence, can be added, merged, or left out altogether (e.g., not all described operations or events are necessary for the practice of the algorithm). Moreover, in certain embodiments, operations or events can be performed concurrently, e.g., through multi-threaded processing, interrupt processing, or multiple processors or processor cores or on other parallel architectures, rather than sequentially.

The various illustrative logical blocks, modules, routines, and algorithm steps described in connection with the embodiments disclosed herein can be implemented as electronic hardware, computer software, or combinations of both. To clearly illustrate this interchangeability of hardware and software, various illustrative components, blocks, modules, and steps have been described above generally in terms of their functionality. Whether such functionality is implemented as hardware or software depends upon the particular application and design constraints imposed on the overall system. The described functionality can be implemented in varying ways for each particular application, but such implementation decisions should not be interpreted as causing a departure from the scope of the disclosure.

The steps of a method, process, routine, or algorithm described in connection with the embodiments disclosed herein can be embodied directly in hardware, in a software module executed by a processor, or in a combination of the two. A software module can reside in RAM memory, flash memory, ROM memory, EPROM memory, EEPROM memory, registers, hard disk, a removable disk, a CD-ROM,

or any other form of a non-transitory computer-readable storage medium. An example storage medium can be coupled to the processor such that the processor can read information from, and write information to, the storage medium. In the alternative, the storage medium can be integral to the processor. The processor and the storage medium can reside in an ASIC. The ASIC can reside in a user terminal. In the alternative, the processor and the storage medium can reside as discrete components in a user terminal.

Conditional language used herein, such as, among others, “can,” “could,” “might,” “may,” “e.g.,” and the like, unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain embodiments include, while other embodiments do not include, certain features, elements and/or steps. Thus, such conditional language is not generally intended to imply that features, elements and/or steps are in any way required for one or more embodiments or that one or more embodiments necessarily include logic for deciding, with or without author input or prompting, whether these features, elements and/or steps are included or are to be performed in any particular embodiment. The terms “comprising,” “including,” “having,” and the like are synonymous and are used inclusively, in an open-ended fashion, and do not exclude additional elements, features, acts, operations, and so forth. Also, the term “or” is used in its inclusive sense (and not in its exclusive sense) so that when used, for example, to connect a list of elements, the term “or” means one, some, or all of the elements in the list.

Conjunctive language such as the phrase “at least one of X, Y and Z,” unless specifically stated otherwise, is to be understood with the context as used in general to convey that an item, term, etc. may be either X, Y, or Z, or a combination thereof. Thus, such conjunctive language is not generally intended to imply that certain embodiments require at least one of X, at least one of Y and at least one of Z to each be present.

While the above detailed description has shown, described, and pointed out novel features as applied to various embodiments, it can be understood that various omissions, substitutions, and changes in the form and details of the devices or algorithms illustrated can be made without departing from the spirit of the disclosure. As can be recognized, certain embodiments of the inventions described herein can be embodied within a form that does not provide all of the features and benefits set forth herein, as some features can be used or practiced separately from others. The scope of certain inventions disclosed herein is indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.

What is claimed is:

1. A depth of consciousness monitor configured to determine a level of sedation of a medical patient, the depth of consciousness monitor comprising:

an EEG interface configured to receive an EEG signal from an EEG sensor;

an EEG front end configured to pre-process the EEG signal, wherein the EEG signal is assigned a first time stamp;

a processor, configured to determine the level of sedation of the medical patient based at least upon the pre-processed EEG signal, the processor comprising:

two or more parallel computing engines, each configured to receive as an input a same first time stamped

23

pre-processed EEG signal and compute a possible sedation level according to a different processing approach, each processing approach configured to simultaneously calculate the possible sedation level using the same first time stamped pre-processed EEG signal; and

- a decision logic module, configured to arbitrate the possible sedation level computations as computed by the two or more parallel computing engines on the same first time stamped pre-processed EEG signal and based on the arbitration, determine a patient sedation index corresponding to an estimated level of sedation of the medical patient, wherein the arbitration comprises selecting a subset of possible sedation levels generated by the two or more parallel compute engines, wherein the arbitration is based at least on data associated with at least one sedation drug acting on the medical patient and the selected subset of possible sedation levels generated by the two or more parallel compute engines; and
 - a data port configured to transmit the level of sedation of the medical patient.
2. The depth of consciousness monitor of claim 1, wherein the data port comprises a multi-parameter physiological

24

monitor interface configured to receive power from a multi-parameter physiological monitor and provide at least the level of sedation of the medical patient to the multi-parameter physiological monitor.

3. The depth of consciousness monitor of claim 1, wherein at least one of the computing engines is configured to implement a motion vector process to compute one of the possible sedation levels.

4. The depth of consciousness monitor of claim 1, wherein at least one of the computing engines is configured to implement a phase coherence process to compute one of the possible sedation levels.

5. The depth of consciousness monitor of claim 1, wherein at least one of the computing engines is configured to utilize a brain model to compute one of the possible sedation levels.

6. The depth of consciousness monitor of claim 1, wherein the EEG front end comprises an EEG engine and an EMG engine configured to extract EEG information and EMG information from the EEG signal, respectively.

7. The depth of consciousness monitor of claim 1, wherein the data port comprises a display.

8. The depth of consciousness monitor of claim 1, wherein the data port comprises a wireless communication device.

* * * * *